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Abstract 
The anthraquinone di-N-oxide AQ4N is a prodrug designed to be 
excluded from cell nuclei until metabolised in hypoxic tumour regions to 
AQ4, a DNA binder and potent inhibitor of topoisomerase II. The 
antitumour effects of AQ4N in rodent neoplasms are well characterised 
but the identity of enzymes responsible for the metabolism are unknown. 
The aims of the present work were to identify Cytochrome P450 (CYP) 
enzymes responsible for AQ4N metabolism in rat and human tissue and 
to conduct a preliminary investigation into the in vivo metabolism of 
AQ4N in tumour bearing rodents. 
AQ4N was found to undergo a two electron reduction to the mono-N-
oxide AQM followed by a subsequent two electron reduction to cytotoxic 
AQ4. The process occurred in the microsomes of rat and human liver, 
was cofactor dependent and was inhibited by air. In rats, CYPs 2B and 
2E were found to anaerobically metabolise both AQ4N and AQM. 
Kinetically, AQ4N metabolism conformed to a Michaelis-Menten model 
whereas the metabolism of AQM was better described by a sigmoidal 
relationship. In addition, both semi purified Cytochrome P450 reductase 
(CPR) and purified Nitric oxide synthase (NOS) were both able to 
anaerobically metabolise AQ4N. Both enzymes required NADPH and 
CPR mediated metabolism was dependent on the presence of exogenous 
haem. 
In humans, the anaerobic metabolism of both AQ4N and AQM correlated 
with CYP 3A activity and not with the activities of CYP 1 AI 2C and 2D. 
AQM metabolism correlated also with the activity of CYP 2A. The 
involvement of CYP 3A was confirmed by the use of CYP specific 
inhibitors and by the use of cDNA transfected cell microsomes. Human 
kidney and colonic tumours were found to anaerobically metabolise 
AQ4N and tumour metabolism was inhibited by the CYP inhibitor carbon 
monoxide (CO). Finally, the in vivo metabolism of AQ4N was studied in 
C3H tumour bearing mice. Metabolites of AQ4N were found in all tissues 
studied but the AQ4! AQ4N ratio was highest in the tumours. 
Collectively, these findings have identified the enzymes responsible for 
the metabolism of AQ4N and its mono-N-oxide. Differences exist 
between the CYP isoforms responsible for metabolism in rodents and in 
man, in humans, CYP 3A enzymes predominantly metabolise AQ4N and 
this subfamily of CYP are known to be well expressed in a broad 
spectrum of human cancers. With this in mind, AQ4N based therapy 
should be considered as a rational treatment regime for patients bearing 
solid tumour burdens. 
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Chapter 1 
1 
Chapter 1 
Introduction 
1.1 Cancer 
In its broadest sense, cancer can be described as a group of diseases in 
which host cells become autonomous from normal growth control 
mechanisms (Holleb et a/1991). It has been estimated that 1 in 3 people 
will develop cancer during the course of their lives. In 1993, cancer 
claimed the lives of 161,770 people in the United Kingdom and, of these, 
lung cancer was the commonest male cancer, accounting for 30% of 
cancer mortality in men, and breast cancer was the most common female 
cancer, accounting for 190/0 of the cancer mortality in women (CRC 
Scientific yearbook 1996). 
1.2 Conventional cancer treatments 
Cancer treatments fall into three main categories, these are: Surgery, 
radiotherapy and chemotherapy. 
Surgery is the oldest form of cancer treatment and is used in the 
diagnosis, staging and physical resection of malignant disease 
(reviewed by Eberlein and Wilson 1991). At present, more than 60% of 
patient with confirmed malignancy undergo some form of surgery 
(reviewed by Eberlein and Wilson 1991). Radiotherapy is a treatment 
regime which utilises ionising radiation, such as X- rays or gamma rays, 
to damage the nucleic acid of cancer cells. Lethal injury to DNA can 
occur by direct ionisation of the DNA molecule by a scattered electron or 
by an indirect mechanism whereby a photon interacts with a water 
molecule producing hydroxyl radicals. The short lived hydroxyl radicals 
2 
are able to interact with and damage cellular DNA (reviewed by 
Hendrickson and Withers 1991). 
Modern chemotherapy originates from the 1940s when nitrogen 
mustards were developed during World War II as chemical warfare 
agents. Treatment of transplanted lymphosarcoma in mice with nitrogen 
mustards revealed that such tumours rapidly regressed (reviewed by 
Montgomery 1979). These early findings prompted the first clinical trial of 
these compounds conducted in a group of six patients with terminal 
neoplastic disease. In two of these individuals, a rapid dissolution of 
large tumour masses followed mustard administration (reviewed by 
Gilman and Philips 1946). Since then, numerous anticancer agents 
have been developed which work by direct or indirect action upon the 
nucleic acids of proliferating cells (reviewed by Cooper and Cooper 
1991). Table 1 lists some clinically useful anticancer agents 
Unfortunately, a growing tumour may consist of only a small fraction of 
proliferating cells at anyone time, thus limiting the efficacy of these 
agents. In order to understand the full implications of this behaviour two 
aspects of tumour growth.are further discussed. 
1.2.1 Stem cell model of tumour growth and Gompertzian 
kinetics 
Firstly, the stem cell model of tumour growth suggests that a hierarchy of 
cancer cells exist within any given tumour. The hierarchy consists of 
highly proliferative stem cells, with little or no specialised function and 
highly specialised (well differentiated) cells with little or no proliferative 
ability. A large subpopulation of the stem cells may be out of cell cycle in 
Go and can only enter cycle at G1 upon a suitable physiological stimulus 
3 
(such as reduced cell number). Therefore, a tumour with a large number 
of cells in Go may be largely refractory to anti proliferative agents. 
Conversely, a tumour with a high proportion of cells in cell cycle may be 
more sensitive to the same treatment (reviewed by Cooper and Cooper 
1991 and Dorr and Fritz, 1982). See Fig 1 a. 
Table 1) Clinically used anticancer agents (Adapted from Franks and 
Teich 1991) 
Classification 
Alkylating agents 
Anti metabo lites 
Plant alkaloids 
Antibiotics 
Nitrosoureas 
Enzymes 
Random synthetics 
Drug 
Mechlorethamine 
Busulphan 
Chlorambucil 
Cyclophosphamide 
Melphalan 
Thiotepa 
Methotrexate 
6- mercaptopurine 
Thioguanine 
5-fluorou racil 
Cytosine arabinoside 
5-azacytidine 
Vinblastine 
Vincristine 
Mitomycin C 
Doxorubicin 
Daunorubicin 
Bleomycin 
Carmustine 
Lomustine 
Semustine 
Streptozotocin 
L-asparaginase 
Cis- platinum diammine dichloride 
Dacarbazine 
Dibromomannitol 
Hexamethylmelamine 
Mitoxantrone 
Hydroxyurea 
Secondly, the growth of many tumours can be fitted to a model of growth 
behaviour known as Gompertzian growth (Rygaard and Spang-
4 
Thomsen 1997), see fig 1 b. The model predicts that at the beginning of a 
tumours life span, well before clinical detection, it grows exponentially, 
having a large subpopulation of cells in cell cycle and fewer in Go. 
However, by the time the tumour becomes detectable the rate of growth 
has slowed and many of the cells that were in cycle have now moved 
back to Go (Tancock and Hill, 1987). This slowing down of growth 
(reduction in proliferative subpopulation) can be attributed to inhibitory 
cell- cell contacts, decreased nutrient supply, toxic metabolite build up 
and tumour hypoxia (Holleb et a1.1991). The result is that the potential 
target for antiproliferative agents is now smaller (8assukas et al 19941 
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1.3 Tumour Hypoxia 
The existence of hypoxic cells within solid tumours was first suggested by 
Thomlinson and Gray in 1955 who analysed human bronchiogenic 
carcinoma specimens and found that tumour cords with a diameter> 200 
J.1m contained areas of central necrosis. Moreover, tumour cords with 
diameters> 160 J.1m contained no necrotic areas. Based on their findings 
they calculated that oxygen could diffuse a distance of approximately 
150 J..lm in respiring tissue and concluded that viable tumour cells found 
on the edge of necrotic regions were probably severely hypoxic. 
Direct evidence for hypoxic tumour cells came from the radiobiological 
experiments of Powers and Tolmach in 1964. Using mouse implanted 
lymphosarcomas, they found that cells from irradiated tumours produced 
survival curves that were biphasic with respect to cell sensitivity and 
resistance. However, when irradiated tumour cells were obtained from 
mice exposed to high oxygen concentrations the resultant cell survival 
curves showed a reduction in the resistant subpopulation of cells. This 
led them to conclude that the transplanted tumours were heterogeneous 
with respect to the degree of oxygenation. 
Oxygen deficiency in tumour cells is thought to arise in one of two ways .. 
Firstly, as the tumour mass enlarges the rate of endothelial cell division 
(neovascularisation) is exceeded by the rate of tumour growth. This 
results in compromised microcirculation to a number of the malignant 
cells. Cells at a distance of between 120- 150 Jlm from an oxygenated 
blood vessel are believed to experience varying degrees of chronic 
hypoxia (Sartorelli 1986). Alternatively, the growth of the tumour itself 
may render cells transiently hypoxic (acute hypoxia) by intermittently 
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compressing a vascular network supplying a subpopulation of the 
neoplastic cells (Sutherland and Franko 1980). 
Most solid tumours are believed to possess a hypoxic subpopulation of 
cells making up between 5 and 30 % of the total tumour mass (Sartorelli 
1986). Indeed a large number of reports have appeared in the literature 
to document the extent of hypoxia within tumours of both human and 
animal origin. The work of Wendling et al {1984) compared red blood 
cells (RBC's) from the microvessels of a large number of normal and 
neoplastic rectal tissue and found the medians of oxyhaemoglobin 
saturation curves from RBC's decreased from 80% saturation, in normal 
tissue, to 49% in malignant. The median partial pressure of oxygen (p02) 
in a range of clinically resected cervical cancers has been found to be 
significantly lower.than corresponding healthy tissue, see Fig 2 (Kolstad 
et a/1968, Bergsjo and Evans 1971, reviewed by Vaupel et a/1989). 
1.3.1 Hypoxic cells and radio/chemoresistance 
The failure of certain tumours to respond to radiotherapy 
(radioresistance) is believed to be a consequence of hypoxic cells (Hall 
1975). In well oxygenated tissue, the effects of ionising radiation can 
lead to the production of superoxide radicals (02--)' These superoxide 
radicals can be "fixed" to form more stable peroxyl radicals (R02-) which 
in turn are free to mediate cellular damage by interacting with cell 
membranes, DNA and other macromolecules (Halliwell and Gutteridge 
1989). In oxygen deficient cells, peroxyl radical formation is minimised 
and, as a result, hypoxic cells escape damage (Hellman 1993). 
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In addition to radioresistance, hypoxic cancer cells may become 
chemoresistant. The increased distance between a chronically hypoxic 
cell (compared to a normoxic cell) and a oxygenated blood vessel may 
exceed the distance a therapeutic agent can diffuse. In this respect, the 
hypoxic subpopulation are able to evade the action of the drug (Sartorelli 
et al 1995). In 1974, Bedford and Mitchell carried out some elegant 
experiments on the effect of hypoxia on chinese hamster ovary (CHO) 
cells and demonstrated that the percentage of cells in S phase decreased 
with the duration of hypoxic exposure and that the same cells spent a 
disproportionate time in G1 and Go (out of cycle). Similar results were 
obtained from the laboratories of Born et al (1979) and Koch et al (1973). 
Collectively, these observations suggested that the sluggish nature of the 
cell cycle under hypoxia may create a situation in which an anticancer 
drug, if able to reach its cellular target, may be ineffective as the cell is at 
an inappropriate stage of cycle. 
Additionally, elevated reduced glutathione (GSH) content may confer 
resistance upon hypoxic cells to anticancer drugs. Using a subclone of 
the A2780 human ovarian carcinoma cell line, a 50 fold elevation of GSH 
has been shown to cause a 1000 fold increase in resistance to cisplatin 
(Godwin et al 1992). Furthermore, exposure of HT 29 adenocarcinoma 
cells to hypoxic conditions has been reported to elevate intracellular 
GSH (O'Dwyer et a/1994). 
Hypoxia mediated induction of gene expression may provide yet another 
mechanism whereby oxygen deficient cancer cells can become 
chemoresistance. For example, the upregulation of DT diaphorase 
(DTD) in adenocarcinoma cells exposed to hypoxia has been reported 
(O'Dwyer et a/1994). In this respect the elevated amount of DTD may be 
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able to detoxify a wide variety of anticancer drugs by virtue of a two 
electron reduction process (Reviewed by Ross et al 1993 and Joseph et 
a/1994). 
1.3.2 Hypoxia inducible factor 1 (HIF- 1) 
Tumour cells are able to adapt to hypoxia by the activation of a 
heterodimeric protein known as hypoxia inducible factor- 1 (HIF- 1). This 
transcription factor, composed of an alpha and beta subunit, HIF- 1 alpha 
and HIF- 1 beta respectively, is constitutively expressed under conditions 
of both normoxia and hypoxia (Huang et a/1996). However, the stability 
of HIF- 1 alpha protein is increased during hypoxia (Huang et al 1996) 
facilitating the dimerisation of both subunits, and subsequent binding of 
functional HIF- 1, to a number of promotor/enhancer sequences 
upstream of genes important for adaptation to low oxygen tensions 
(reviewed by Jiang et al 1997). Amongst the genes transcriptionally 
activated by HIF- 1 are the vascular endothelial growth factor 
glycoproteins (VEGF) (Forsythe et a'-1996). VEGF proteins bind to the flt-
1 and flk- 1 receptors on endothelial cells (Seetharam et al 1995, 
Rockwell et a/1995 and reviewed by Cheng et a/1996) and in so doing 
initiate a signal transduction system which leads to cell proliferation and 
neovascu larisation. 
1.4 Tumour hypoxia as a target for bioreductive drugs 
In 1936 it was shown that microbial cultures grown anaerobically had 
lower half wave redox potentials, and hence a greater capacity for 
reduction, than microbial cultures grown aerobically (Hewitt 1936, 
reviewed by Kennedy et a/1980). These early findings led Lin and co 
workers to speculate that hypoxic cells remote from the vascular supply 
of a tumour mass might, in an analogous way to anaerobic microbes, 
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have a greater capacity for reductive reactions compared to well 
oxygenated cells. The same workers then went on to synthesis the first 
bioreductive agents which were a series of benzo- and naphthoquinones 
(Lin et a/1972). These compounds were found to be potent inhibitors of 
both DNA and RNA synthesis in adenocarcinoma 755 cells and 
prolonged the life span of such tumour bearing mice (Lin et al 1972). 
Since the early seventies the concept of bioreductive drug activation has 
been viewed as a potential treatment regime whereby hypoxic tumour 
cells can be selectively destroyed. Ideally, the bioreductive agent, 
referred to as a prodrug (Workman 1992) should possess certain 
properties which are outlined below (reviewed by Friery 1997):-
1) It should not be toxic to normal oxygenated tissue. 
2) It should be converted irreversibly to a stable oxygen insensitive 
cytotoxin under conditions of hypoxia. 
3) The cytotoxic metabolite should maintain activity upon 
reoxygenation of tumour cells or upon diffusion away from the primary 
hypoxic region. 
4) The cytotoxic metabolite should remain within the tumour tissue 
and not diffuse into normal surrounding tissue. 
5) It should exert cytotoxic activity against acute and chronic hypoxic 
cells. 
The following paragraphs review four classes of bioreductive agents 
namely: nitroheterocyclics, heterocyclic N-oxides, quinones and the 
1 1 
newly developed anthraquinone di N-oxides. Enzymes involved in 
bioreductive activation are discussed in section 1.2.2. 
1.4.1 N itroheterocycl ics 
RSU 1069 and its prodrug RB 6145 are both examples of this class of 
compound (Adams et at 1994), see Figure 3 Both agents have been 
shown to be preferentially toxic to hypoxic cells although the precise 
details of the bioactivation process remain, at present, unclear (Workman 
and Stratford 1993). Furthermore, both agents potentiate the effect of 
radiotherapy when used in the KHT rodent tumour model (Bremner 
'1993). RB 6145 is reported to be better tolerated in mice and less emetic 
in dogs than RSU 1069. In addition, both compounds are able to 
enhance the effect of photodynamic therapy (PDT) on the growth delay of 
RIF- 1 murine sarcomas (Bremner 1993). 
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Fig 3. Structures of A) RSU 1069 and B) RB 6145 
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1.4.2 Heterocyclic N-oxides 
Tirapazamine (SR 4233), the lead compound available in this class, has 
been shown to potentiate the anti tumour activity of radiotherapy 
(reviewed by Siim et al 1997) and enhance the sensitivity of 
transplantable murine neoplasms to various antineoplastic agents 
including: carboplatin, cyclophosphamide, doxorubicin, etoposide and 
taxol (Dorie and Brown 1997). In addition, SR 4233 has been shown to 
have a marked effect on the growth delay of the T50/80 and RIF-1 
neoplasms (Mc Keown et al 1996 and Brown and Lemmon 1990). 
Presently, tirapazamine is undergoing a phase II clinical trial in 
combination with radiotherapy and a phase III trial in combination with 
the anticancer drug cisplatin (reviewed by Siim et a/1997). 
SR 4223 is extensively metabolised under hypoxic conditions (Baker et 
a/1988) and is 75 to 200 times and 15 to 50 times more toxic to hypoxic 
rodent and human cell lines respectively, compared to normoxic controls 
(Zeman et a/1986). Mechanistically, the drug undergoes a one electron 
reduction to form a reactive nitroxyl radical. In air, the radical can be 
back oxidised to SR 4233 with the subsequent generation of a 
superoxide radical. In the absence of air, the one electron reduced 
radical mediates a hydrogen abstraction from a cellular macromolecule 
such as DNA, to form the two electron reduced molecule SR 4317. The 
hydrogen abstraction causes single and double strand breaks within 
DNA and this, in turn, leads to cell damage (Elwell et a/1997). SR 4317 
can be further metabolised via a two electron reduction to form the stable 
product SR 4330 (Naylor 1994 and Costa et a/1989). The mechanism of 
SR 4233 bioactivation is depicted in Figure 4. 
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1.4.3 Quinones 
Mitomycin C (MMC) and porfiromycin are both antineoplastic antibiotics 
isolated from Streptomyces caespitosus (Sartorelli 1986). The drugs are 
preferentially more toxic to murine EMT6 tumour and V79 chinese 
hamster lung fibroblasts under hypoxic conditions but MMC appears to 
be equitoxic to chinese hamster ovary (CHO) cells in the presence and 
absence of oxygen (Keyes et a/1984). MMC has been shown to improve 
the effect of radiotherapy in patients with cancers of the head and neck 
(reviewed by Sartorelli et a/1995). 
MMC may be considered as the prototype bioreductive alkylating agent 
and both MMC and porfiromycin are bioactivated via a one or two 
electron reduction which generates intermediates capable of producing 
interstrand cross links between complementary DNA strands (Iyer and 
Szybalski 1964), see Figure 5. These cross links are considered to be 
the major cause of anti tumour activity (Iyer et a/1964, reviewed by Lin et 
al 1972). Toxicity of both drugs under aerobic conditions occurs from 
redox cycling, where the presence of molecular oxygen facilitates the re-
oxidation of the semiquinone radical to the parent compound with the 
liberation of a superoxide radical. In the presence of ferrous ions the 
superoxide radical can be converted to hydroxyl radicals which are able 
to damage DNA, protein and cell membranes (Kappus 1986). 
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1.4.4 The development of AQ4N (1,4-bis-{[2-(dimethylamino-
N-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9, 1 O-dione), a 
novel anthraquinone di-N-oxide based prodrug and structural 
analogue of mitoxantrone. 
The antitumour effects of the 1,4- bis substituted anthraquinones have 
been well documented and are reviewed by Wiseman and Spencer 
(1997), and Dunn and Goa (1996). Included in this class of compounds 
are mitoxantrone (NSC 301739) and the related analogue ametantrone, 
(Figure 6). Both compounds possess a planar electron deficient 
anthraquinone chromophore and are thought to exert toxicity by 
intercalation of the chromophore between electron rich DNA bases 
(Johnson et al 1979 and Patterson 1993). The 1,4 bis substituted 
alkylamino side chains are cationic and enhance the strength of the 
drug/DNA complex by non-covalently interacting with the deoxyribose 
phosphate backbone of DNA (Denny and Wakelin 1990). The 5,8-
dihydroxy substituents of mitoxantrone aid tighter binding of the drug to 
DNA and this is thought to explain the ten fold increase in toxicity of 
mitoxantrone, compared to analogues, to a range of transplantable 
murine neoplasms (Johnson et a/1979). 
Mitoxantrone has been shown to inhibit DNA and RNA dependent 
polymerases in a variety of cultured cell lines (Traganos et al 1980 and 
Foye et a/1982), topoisomerases in human breast cancer cells (Crespi et 
al 1986) and elicit DNA single and double stranded breaks in murine 
1210 leukaemia cells (Cohen et a/1980), an observation consistent with 
the general inhibition of DNA synthesis. 
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Although a number of anthraquinones, such as doxorubicin, have been 
shown to undergo one electron reduction and subsequent redox cycling 
there is no convincing evidence to suggest that either mitoxantrone or 
ametantrone are subjected to the same fate (reviewed by Patterson 
1993). Neither compound, compared to doxorubicin, generates 
detectable free radicals in MCF-7 cells (Fisher and Patterson 1990). 
Conversely, evidence of oxidative activation has been published (Reska 
et a/1989). The apparent lack of redox cycling observed in cells treated 
with mitoxantrone has, in part, prompted the development of a series of 
tertiary amine-N-oxide analogues of this compound which can be 
'considered as bioreductive prodrugs. The rationale behind this idea is 
that the N-oxide functionality masks the cationic charge of the amine 
group. Under anaerobic conditions these compounds undergo reductive 
activation to yield a cytotoxic tertiary amine. 
The lead compound in this series is AQ4N, a prodrug scheduled to enter 
clinical trial in 1998. AQ4N has been shown to be inactive aerobically in 
V79 cells in vitro as the partial negative charge on the N-oxide group is 
repulsive to the partial charge on the phosphate groups of DNA 
(Patterson et al 1994). This property makes the prodrug a poor DNA 
binding agent, consistent with the inability of AQ4N to elevate the melting 
temperature of calf thymus DNA (Patterson 1993). Under hypoxic 
conditions, and in the presence of NADPH supplemented liver 
microsomes, AQ4N undergoes a two electron reduction to yield the 
mono-N-oxide AQM, followed by a second two electron reduction to 
produce the cytotoxic tertiary amine AQ4 (Fig 7), which, unlike its N-
oxide, is retained in cell nuclei (Smith et al 1997), binds to DNA, has 
similar cytotoxic activity in vitro to mitoxantrone and is a potent inhibitor of 
V79 topoisomerase II (Patterson et a/ 1992). The prodrug nature of 
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AQ4N has been investigated in a variety of murine models. Using 
B6D2F mice bearing the T50/80 mammary carcinoma the antitumour 
effect of AQ4N was potentiated in vivo by combination with hypobaric 
hypoxia (McKeown et al 1995). The same workers reported reduced 
systemic toxicity when using AQ4N compared to the other bioreductive 
drugs RSU 1069 and tirapazamine. 
AQ4N and other bioreductives have also been investigated in clamped 
RIF-1, KHT and SCCVII neoplasms. Using this approach, Cole and 
coworkers (1995) were able to maximise the hypoxic subpopulation of 
cell within the tumour (via the clamp) and so study the effect of each 
bioreductive used singly or in combination with radiation. They 
discovered that AQ4N alone (250 mg/kg) had a significant effect on the 
growth delay of RIF-1 and SCCVII tumours. Furthermore, following a 
dose of 25 Gy radiation the growth delay of these tumours was greatly 
enhanced in the presence of AQ4N (Cole et a/1995). 
The antineoplastic effects of three N-oxide prodrugs namely: nitracine N-
oxide (NC-NO), AQ4N and N-2-[(dimethylamino)ethyl] acridine-4-
carboxamide DACA (NSC 601316) have been evaluated with respect to 
their ability to kill cells from a number of rodent and human cell lines and 
to retard the growth of the MDAH- MCA- 4 mammary carcinoma. All three 
compounds were found to be cytotoxic to the cell lines under conditions 
of hypoxia. However, AQ4N was found to be superior to the other 
compounds in retarding the growth of the mammary tumour with or 
without a single dose (20Gy) of radiation prior to the drug treatment 
(Wilson et a/1996) 
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1.5 Enzymology of bioreductive drug activation. 
The effectiveness of hypoxia directed bioreductive therapy will be 
enhanced by identifying tumours that express high levels of appropriate 
reductase enzymes (Workman and Walton 1990). The following 
discussion reviews enzyme systems known to mediate the reductive 
metabolism of a number of pre- clinical and clinically relevant 
bioreductives. Furthermore, a number of enzyme systems that may have 
potential as bioreductases are also reviewed. 
1.5.1 Aldehyde oxidase (AO) 
Aldehyde oxidase (AO) is a molybdenum containing flavoprotein known 
to be located in the cytosolic compartment of mammalian cells (Wolpert 
et a/1973). The enzyme is able to catalyse the oxidation of a range of 
aldehydic and N-heterocyclic substrates (reviewed by Wolpert et al 
1973). Furthermore, AO has been reported to catalyse the two electron 
reduction of SR 4233 to SR 4317 under anaerobic conditions (Walton 
and Workman 1990). 
1.5.2 NADH: Cytochrome bs reductase. 
NADH cytochrome bS is an enzyme which catalyses the NAD+ 
dependent reduction of cytochrome bS from the ferric state (+3) to the 
ferrous state (+2). The enzyme, isolated from rabbit erythrocytes, has 
been shown to metabolise mytomycin C to metabolites which are 
capable of alkylating 4-(p-nitrobenzyl) pyridine (PNBP) (Hodnick- and 
Sartorelli 1993). The metabolism was found to have a pH optimum of 
6.0, conform to Michaelis-Menten kinetics and was inhibited by 
dicoumarol in a concentration dependent manner. In addition, the 
alkylation of PNBP was shown to occur 1.S times greater under hypoxic 
conditions (Hodnick and Sartorelli 1993). 
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NADH: cytochrome bs reductase has been immunochemically detected 
in a number of clinically resected human brain tumours (Rampling et al 
1993). The same workers found that these tumours have significant 
regions of hypoxia and concluded that human brain tumours may be 
ideal candidates for bioreductive therapy. 
1.5.3 Xanthine dehydrogenasel Xanthine oxidase (XDHI XO) 
Xanthine dehydrogenase (XDH), a cytosolic molybdenum containing 
hydroxylase, is found in the cytosol and catalyses the rate limiting step in 
purine catabolism. Specifically, the enzyme hydoxylates hypoxanthine to 
xanthine followed by hydroxylation of xanthine to uric acid.(Pritsos and 
Gustafson 1994}. The reaction is NADH dependent unlike the identical 
reaction catalysed by xanthine oxidase (XO) which is oxygen dependent 
and liberates two molecules of superoxide radicals (Pritsos and 
Gustafson 1994). Purified xanthine oxidase (XO) has also been shown 
to catalyse SR 4233 to both the two (SR4317) and the four (SR4330) 
electron reduced metabolites under hypoxic conditions (Walton and 
Workman 1990). 
XDH has been shown to catalyse mytomycin C via a two electron 
reduction forming the stable metabolite 2,7-diaminomitosene (Gustafson 
and Pritsos 1992). The metabolism again occurs more readily under 
hypoxia and the effect of mytomycin C concentration on velocity of 
reaction produces rectangular hyperbolic plots consistent with Michaelis-
Menten kinetics (Gustafson and Pritsos 1993). The optimum pH for the 
reaction is found to be 6 and metabolism at pH 7.4 causes a doubling in 
Km (halving of enzyme affinity) and a halving of V max (Gustafson and 
Pritsos 1993). 
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A number of reports have documented a decreased level of XDH in a 
number of tumours from a variety of species. For example, decreased 
XDH protein has been described in two rat neoplasms, namely 
hepatoma 3924A (fast growing}and hepatoma 20 (slow growing) where 
levels of the protein were 20/0 and 33% of values observed in normal 
livers respectively (Ikegami et a/1986). Decreased XDH has also been 
reported in mouse colon (Weber et a/1978) and human kidney tumours 
(Weber et a/1977). 
1.5.4 NAO{P)H: Quinone Oxidoreductase (OT diaphorase or 
NQO) 
NOO activity was first reported in 1958 by Ernster and Navazio. Since 
then, four isozymes have been identified and are the products of 
separate gene loci designated D1A 1 to DIA 4 (Edwards et a/1980). The 
protein product of DIA 4 has also been well studied and is referred to as 
NO 01 (Riley and Workman 1992a). N001 exists as a dimeric 
flavoprotein with a molecular mass of around 55 KDa. Activity is 
predominantly located in the cytosolic fraction (>90%) where it links the 
oxidation of NADH or NADPH, with equal preference, to the obligate two 
electron reduction of quinones and their derivatives (Riley and Workman 
1992 a). In this respect NOO activity has a cytoprotective function limiting 
the formation of semiquinones and oxygen free radicals and so reducing 
oxidative stress (Ross et a/1993 and Riley and Workman 1992 a). The 
protective function of NOO has been demonstrated in cDNA transfection 
studies of COS-1 cells, where cells transfected with cDNA for N001 
prevent the binding of damaging semiquinones to DNA by eliminating 
their formation (Joseph et a/1994). 
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NQO·s have also been implicated in the bioactivation of a variety of 
antitumour agents including mytomycin C (Workman and Walton 1990). 
However, the role of these enzymes in the metabolism of MMC remains 
controversial (Workman and Walton 1990 and Workman et a/1989). The 
controversy centres around the effectiveness of dicoumarol as a specific 
inhibitor of NQO in experiments using subcellular fractions. Interestingly 
though, studies using purified rat and human NQO·s have clearly shown 
that the enzyme is capable of bioactivating mytomycin C, mytomycin A, 
streptonigrin, CB 1954 and diaziquone (Beall et al 1994). The 
metabolism of MMC by NQO·s was shown to induce cross linking of 
pBR322 DNA (Beall et a/1994). Although antitumour quinones E09 and 
E04 are both substrates for purified rat and human NQO·s (Phillips 
1996).only E04 could produce cross linking of pKK233- 2 DNA following 
incubation with human or rat NQO. E09, on the other hand, could only 
induce cross linking of DNA following incubation with the rat enzyme 
(Phillips 1996) 
The metabolism of SR 4233 (figure 4) has also been shown to be 
mediated by NQ01 purified from Walker 256 rat tumour cells (Riley and 
Workman 1992 b). The main products of this metabolism are the two (SR 
4317) and four (SR 4330) electron reduced metabolites. As neither of 
these two metabolites are cytotoxic under conditions of hypoxia or 
normoxia, cells expressing high levels of NQO·s may well be protected 
against this agent (Riley and Workman 1992 b). 
Human NQ0 1 is an inducible enzyme and its regulation is governed by a 
promoter sequence which contains a number of cis controlling elements 
(Figure 8 A). The induction of the enzyme by environmental and 
endogenous compounds has been reviewed by Joseph and co-workers 
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(Joseph et a/1994). The same laboratory has formulated a hypothetical 
model for the induction of N001 (Figure 8 8). 
NOO activity has been reported in brain tumours (Rampling et a/1993), 
and colorectal tumours (De Waziers et a/1991), is increased in colon 
tumours (Schor and Comelisse 1983) and highly elevated (20-50 fold) in 
hepatoblastomas and hepatocarcinomas (Cresteil and Jaiswal 1993). 
The elevated expression of NOO's detected in these human tumours 
opens up exciting possibilities for the future development of novel 
bioreductives that can be specifically activated by N001 enzymes. 
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1.5.5 NADPH Cytochrome P450 reductase (CPR) 
NADPH cytochrome P450 reductase (CPR) is a flavoprotein with a 
molecular mass of 78 KDa (Backes 1993) each molecule of the enzyme 
contains one molecule of FMN and FAD. The enzyme is an integral 
component of the mixed function oxidase system (MFOS) and is located 
in the endoplasmic reticulum (ER) where its intimately associated with 
cytochrome P450 and cytochrome bs, (Figure 9). The close association 
between CPR and cytochrome P450 is crucial to catalysis as CPR 
catalyses the transfer of electrons from NADPH to cytochrome P450 
(Backes 1993). 
CPR is encoded by a single gene which is highly conserved across 
mammalian species (Porter et al 1990). In rats, CPR levels are 
transcriptionally regulated by thyroid hormone (Ram and Waxman 1992) 
hypophysectomy or treatment with the antithyroid drug methimazole 
which leads to a 75-80% decrease in hepatic and 30-50% decrease in 
extrahepatic activity respectively (Ram and Waxman 1992). 
CPR is a versatile enzyme and, as well as cytochrome P450, catalyses 
the reduction of a number of other substrates including haem oxygenase 
(Schacter et a/1972), cytochrome bs (Enoch and Strittmatter 1979), fatty 
acid elongase (Keyes et a/1979) and cytochrome c (Backes 1993). The 
reduction of oxidised cytochrome c is often used in the laboratory to 
measure CPR activity. Furthermore, CPR can catalyse the oxidative 
catabolism of free haem to biliverdin (Yoshinaga et a/1982, Docherty et 
al 1982 and Guengerich 1978). The latter reaction may assume 
particular importance during periods of haem overload and subsequent 
haem oxygenase saturation (Guengerich 1978). 
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Under hypoxic conditions purified rat CPR has been shown to bioactivate 
SR 4233 to the mono-N-oxide SR 4317 (Walton et a/1992). Indeed a 
human CPR cDNA transfected into human breast cancer cells was able 
to express the 78 KDa protein and confer enhanced sensitivity to both SR 
4233 and RSU 1069 under conditions of hypoxia (Patterson et a/1997). 
In liver microsomes, the metabolism of the same drug was found to be 
inhibited by an inhibitory antibody to CPR (Walton et a/1992). CPR has 
also been implicated in the bioactivation of mytomycin C (Workman and 
Walton 1990) and resistance to this compound in CHO cells has also 
been attributed to decreased levels of CPR (Walton et a/1989) 
To date, only a modest number of laboratories have investigated the 
expression of CPR in neoplastic tissue. For example, the enzyme has 
been found in rat glioma cells (Geng and Strobel 1995),and in human 
breast adenocarcinoma (Patterson et al 1995) and is elevated in colon 
carcinoma relative to normal mucosa (Mekhail- Ishak et a/1989). 
1.5.6 Cytochrome P450 (CYP) 
Cytochrome P450 (CYP) is a collective term used to describe a gene 
superfamily of proteins involved in the oxidative, peroxidative and 
reductive metabolism of a wide range of structurally diverse xenobiotic 
and endogenous compounds (Gonzalez 1989 and Nelson et al 1993). 
CYP was first identified as a reduced hepatic pigment which bound 
carbon monoxide to give a characteristic absorption maxima at 450 nm 
(Klingenberg 1958 and Garfinkle 1958). The reduced pigment was later 
characterised as a haemoprotein and named cytochrome P450 by 
Omura and Sato (Omura and Sato 1964). 
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CPR 
N N 
Substrate 
Fig 9 Association of Cytochrome P450 Reductase (CPR ) and 
Cytochrome P450 in the endoplasmic reticu lu m (E R) (From Jefcoate 
1995). 
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Since the identification of this spectrally apparent haemoprotein, 
numerous isoforms have been purified and characterised with respect to 
their catalytic specificity (Gonzalez 1989). However, until fairly recently, 
GYP research had been hampered by the lack of a systematic method for 
the naming of existing and newly discovered isoforms. To overcome this 
problem, a system of nomenclature has been introduced which 
categorises GYPs based on their primary amino acid sequence 
(reviewed by Nelson 1995). Specifically, any CYP with a sequence 
homology ~ 40% of another CYP is placed in the same family which are 
designated by roman numerals. Furthermore, any GYP with a sequence 
homology ~ 55% of another family member is placed in the same 
subfamily (represented by capital letters). Genes within a subfamily are 
identified by sequential numerals. For example, two genes in the GYP 
1A subfamily are GYP 1A1 and GYP 1A2 respectively (Paine 1991). 
As of 1994, 325 separate GYPs have been sequenced. The sequences 
belong to 50 families, 82 subfamilies and originate from 67 separate 
species (Nelson 1995). In mammals, families 1 to IV encode microsomal 
GYPs involved in xenobiotic metabolism whereas families XI, XVII, XIX 
and XXI code for GYPs involved in endogenous metabolism (Paine 1991 
and Gonzalez 1989). Families 1 to IV will be briefly reviewed below. 
However, the mechanistic nature of GYP catalysis is discussed first with 
particular emphasis on GYP mediated reduction. 
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1.5.6.1 The Catalytic Cycle of CYP 
The oxidative catalysis of a substrate molecule by CYP has been 
extensively discussed (reviewed by Murray and Reidy 1990 and Groves 
and Yuan- Zhang 1995). The essential steps in catalysis are believed to 
follow the sequence (1) Substrate (RH) binding. (2) Reduction of ferric 
Fe3+ to ferrous Fe2+. (3) Binding of dioxygen to give a ferrous CYP-
dioxygen complex. (4) Transfer of a second electron to the complex. (5) 
Protonation and breaking of the 0- 0 bond with subsequent 
incorporation of the distal oxygen atom into a molecule of water and the 
formation of a reactive- oxo species. (6) Finally, transfer of the bound 
oxygen to the substrate and dissociation of the new molecule (ROH) 
away from the active site (Groves and Yuan- Zhang 1995). The catalytic 
cycle is shown in Figure 10. 
);:-
ROH FeH~RH 
(6) (1) 
NADH IT 
'Fe)~RH Fe - RH 
NADH -cytochrome 1 ) 
b5 r.ductase 0;- (2) e-_NADPH-cytochrome-NADPH CY'Od>C._~_~~/)151 / P-ASO c.duda" 
/e \ FeH-RH 
NADPH-cytochrome ~e)~RH 731 ~Ol 
P-450 raductase - ~(4) 
,If °2 Flel~RH 
NADPH 
°2 
Fig 10. Catalytic cycle of CYP mediated metabolism . 
RH= substrate and ROH= the hydroxlated metabolite (From Gibson and 
Skett 1994) 
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Evidence for CYP mediated reduction under anaerobic conditions came 
from investigations using imipramine N-oxide, tiaramide N-oxide, and N, 
N-dimethylaniline N-oxide. All three of these compounds were found to 
be extensively reduced in liver, kidney, lung and intestinal microsomes 
by a process that occurred optimally at physiological pH and 
temperature, showed a preference for NADPH over NADH as reduced 
cofactor, and was inhibited by carbon monoxide and oxygen (Sugiura et 
a/ 1976). In addition, microsomes from phenobarbital treated rats 
metabolised indicine N-oxide with a higher V max than untreated animals, 
the Km for both treated and control remained the same (Powis and 
Wincentsen 1980). Induction/ inhibition studies prompted Powis and 
Wincentsen to speculate on a novel CYP isoform that could reduce 
indicine N-oxide by utilising NADH as cofactor but would not contribute to 
oxidative metabolism (Powis and Wincentsen 1980). Furthermore, 
purified rabbit CYP's reconstituted with CPR have also been shown to 
reduce indicine N-oxide under conditions of hypoxia. 
1.5.6.2 The CYP 1 A subfamily 
In rats, members of the CYP 1 A subfamily are inducible by 3-
methylcholanthrene (3 MC), beta-naphthoflavone (beta-NF), aroclor 
1254 and tetrachlorodibenzo-p-dioxin (TCDD) (Funae and lmaoka 1995 
and Paine 1991). CYP 1 A 1 from both rat and man can catalyse 7-
ethoxycoumarin and 7-ethoxyresorufin O-deethylations (ECOD and 
EROD) (Burke et a/1985). The same enzymes are able to mediate the 
hydroxylation of benzo[a]pyrene (Nebert and Gonzalez 1987). Rat and 
human CYP 1 A 1 are reported to share an amino acid sequence 
homology of 800/0 (reviewed by Soucek and Gut 1992). Human CYP 1 A 1 
is highly inducible in extrahepatic tissue by cigarette smoke(Nedelcheva 
and 
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Gut 1994}. and its induction in lung tissue has been linked to the onset of 
carcinogenesis in heavy smokers (Garcia- Glosas et a/1997). 
Human GYP 1 A2 has 75% sequence homology to the rat orthologue and 
680/0 homology with human 1 A 1 (Spazenegger and Jaeger 1995). GYP 
1 A2 from rat or man is responsible for the catalysis of a number of 
carcinogens to various products (Quattrochi et al 1994) aswell as 
metabolising a range of drugs in clinical use(Nedelcheva and Gut 1994}. 
1.5.6.3 The CYP 18 subfamily 
The GYP 1 B subfamily have only recently been described (Sutter et al 
1994) and to date, only one dioxin inducible member, GYP 1 B 1, is known 
to exist (Sutter et al 1994). GYP 1 B1 will be discussed later with 
reference to its expression in cancer tissue. 
1.5.6.4 The CYP 28 subfamily 
The rat GYP 2B subfamily consists of three separate genes namely 2B1, 
2B2 and 2B3 (Paine 1991). GYP 2B1/2B2 are both inducible by 
phenobarbital whereas 2B3 is refractory to phenobarbital treatment 
(Paine 1991). Rat GYP 2B has been linked to the reductive activation of 
tirapazamine (Walton et a/1992). 
To date, the only 2B enzyme known to be expressed in human liver is 
GYP 2B6 (Mimura et a/1993). As well as nicotine metabolism, GYP 2B6 
is thought to metabolise the oxidative activation of the anticancer drug 
cyclophosphamide (reviewed by Gonzalez 1993). Furthermore, human 
GYP 2B6 overexepressed in Iymphoblastoid cell lines has been shown 
to bioactivate tirapazamine under hypoxic conditions (Lewis et a/1995). 
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1.5.6.5 The CYP 2C subfamily 
Five CYP 2C isoforms are presently known to exist in the rat, namely: 
CYP 2C6, 2C7, 2C11, 2C12 and 2C13 (Gonzalez 1989). CYP 2C11 and 
2C12 are male and female specific respectively and their expression is 
controlled in part by testosterone (Paine 1991 and Gonzalez 1989). CYP 
2C13 is also a male specific isoform, its expression varies considerably 
between individual animals and increases during the onset of sexual 
maturation (Mc Clellan- Green 1989). The rat 2C subfamily members 
have been implicated in the hypoxia dependent activation of 
tirapazamine (Walton et a/1992). 
There appears to be at least six different human CYP 2C isoforms 
(reviewed by Guengerich 1995). The isoforms known are GYP 2G8, 
2C9, 2C10, 2C17, 2C18 and 2C19 (reviewed by Guengerich 1995 and 
Nedelcheva and Gut 1994). Human 2G enzymes are involved in a large 
number of drug biotransformations including the 6 alpha hydroxylation of 
the anticancer drug taxol (Cresteil et al 1994), hydroxylation of (S)-
mephenytoin (Reiling et al 1990) and the 7-hydroxylation of the 
anticoagulant (S)-warfarin (reviewed by Spatzeneggar and Jaegar 
1995). CYP 2C9 is the most abundant 2C form in human liver and has a 
high catalytic activity towards tolbutamide (reviewed by Guengerich 
1995). All human CYP 2C enzymes have a sequence homology which is 
80% identical to each other (Romkes 1991). 
1.5.6.6 The CYP 20 subfamily 
CYP 2D1 and 2D2 have been isolated from untreated male rats 
(Gonzalez 1987). These two isoforms share a sequence identity of 
around 73% and appear to be differentially regulated (reviewed by 
Funae and Imaoka 1995). Humans express CYP 206 and the enzyme 
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has been the focus of much research as it is responsible for the 
debrisoquinel sparteine polymorphism. Approximately 7% of American 
and European Caucasians possess two mutant alleles for CYP 206 and, 
as such, are unable to metabolise debrisoquine, spartein and around 
twenty other drugs (reviewed by Spatzeneggar and Jaegar 1995). The 
expression of functional CYP 206 has also been linked to an increased 
risk of tobacco activated lung cancer (Crespi et a/1991) 
1.5.6.7 The CYP 2E subfamily 
The ethanol inducible CYP 2E enzyme has been identified in rats, rabbits 
and man (reviewed by Nedelcheva and Gut 1994) and all three of these 
proteins share an amino acid sequence homology of around 80% 
(Gonzalez 1989). CYP 2E is able to mediate the catalysis of ethanol, 
acetone and halogenated hydrocarbons (reviewed by Nedelcheva and 
Gut 1994). Moreover, the enzyme has been linked to the activation of a 
number of xenobiotics to damaging electrophilic metabolites that may be 
responsible for the initiation of carcinogenesis (Yang et a/1990 and 
reviewed by Nedelcheva and Gut 1994). For example, the activation of 
N-nitrosodimethylamine (NOMA) and N-nitrosodiethylamine (NOEA) via 
the process of alpha carbon oxygenation have both been reported to 
occur in human cell lines expressing a CYP 2E1 gene (Crespi et al 
1990). Furthermore, the activation of NOMA has been found to correlate 
significantly with the expression of CYP 2E in a panel of sixteen different 
human liver microsome preparations (Yoo et a/1988). Under anaerobic 
conditions CYP 2E, like CYPs 2B/2C and 3A, has also been reported to 
bioactivate the anticancer prodrug SR4233 to a nitroxyl radical which is 
capable of ONA damage (Khan and O· Brien 1995). The bioactivation of 
SR4233 has been discussed in section 1.4.2 and is depicted in Figure 4. 
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1.5.6.8 The CYP 3A subfamily 
In rats two CYP 3A proteins exist, namely CYP 3A 1 and CYP 3A2 (Paine 
1991). Both forms are induced in the liver by phenobarbitone but the 
level of induction is less than that seen for CYP2B enzymes (Paine 
1991). Interestingly, rat CYP 3A 1 is also induced by PCN whereas 3A2 
is refractory to the same treatment (Paine 1991). Rat CYP 3A enzymes 
demonstrate catalytic activity towards testosterone 6-beta-hydroxylation 
(Halvorson et al 1990), ethylmorphine and erythromycin demethylation 
(reviewed by Paine 1991) and nifedipine oxidation (Guengerich et al 
1986). Furthermore, PCN induced rat liver microsomes bioactivate 
SR4233 to the mono-N .. oxide SR 4317 under anaerobic conditions, a 
finding consistent with the involvement of CYP 3A (Walton et a/1992). 
In humans the CYP 3A subfamily currently comprises four separate 
enzymes, namely CYP 3A4, 3A3, 3A5 and 3A7 (reviewed by Li et al 
1995). Human CYP 3A enzymes are constitutively expressed in the liver 
where their expression makes up approximately 30% of total hepatic 
CYP. CYP 3A5 is expressed in about 20% of adult livers. For review see 
Li et al (1995). 
The CYP 3A subfamily are a remarkable group of enzymes as they have 
been implicated in the metabolism of over 50% of drugs administered to 
man (Wacher et a/1995). Interestingly, the CYP 3A mediated catalysis of 
amitriptyline and aflatoxin B1 have both recently been reported to 
conform to sigmoid kinetics (Schmider et al 1995 and Gallagher et al 
1996) implying that CYP 3A enzymes can undergo steric activation in a 
manner more commonly observed in multimeric proteins (Oickins and 
Bayliss 1996). 
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1.5.6.9 The CYP 4A subfamily 
A number of structurally diverse xenobiotics including the industrial 
plasticiser di-2-(ethylhexyl} phthalate, chlorinated phenoxy acid 
herbicides and the hypolipidaemic drug clofibrate induce a rat hepatic 
GYP termed GYP 4A 1 (reviewed by Paine 1991) and (Sundseth and 
Waxman 1992). GYP 4A1 catalyses the terminal (omega) carbon atom 
hydroxylation of medium and long chain fatty acids and has been linked 
to the induction of peroxisome proliferation (reviewed by Sundseth and 
Waxman 1992). The amino acid sequence homology of GYP 4A1 to that 
of the other GYP proteins is less than 35% (Gonzalez 1989) suggesting 
GYP 4A 1 diverged early on in the process of GYP evolution (Paine 
1991 ). 
1.5.7 CYP expression in cancer 
The expression of GYPs in neoplastic tissue has important clinical 
consequences if these enzymes are to be exploited as potential 
therapeutic targets for novel and existing bioreductives. The last few 
years has witnessed an emerging trend within the scientific literature 
documenting the presence of various GYP isoforms in a increasing 
number of cancers both of human and animal origin. In particular, GYP 
1A and GYP 3A have both been detected in human tumours of the colon 
(McKay et al 1993), breast (Murray et a/1993 a), oesophagus, liver 
(reviewed by Wacher et al 1995) and various soft tissue sarcomas 
(Murray et al 1993 b). GYP 3A has been also detected in human lung 
tumours (Kivisto et al 1995) and renal cell carcinomas (G Murray 
personal communication). Indeed a link between GYP 3A and P-
glycoprotein expression in cancer cells has been described by Wacher et 
al (1995). Moreover, the expression of GYP 2A, 28, 2G and 3A have all 
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been reported to be induced In human breast and colon xenografts 
(Smith et a/1993). 
The recently sequenced CYP 1 B 1 enzyme has been reported to be 
highly expressed in a number of human cancers (Murray et a/1997) and 
its expression within these cancers seems to exceed the expression 
observed in paired normal tissue (Murray et a/1997). 
1.6 Enzyme systems with potential to activate bioreductive 
agents. 
Both nitric oxide synthase (NOS), and the cytochrome P450 reductase 
(CPR)/haem oxygenase (HO) system may have the potential to 
reductively activate prodrugs under conditions of hypoxia. These two 
enzyme systems are briefly outlined below. 
1.6.1 Nitric Oxide Synthase (NOS) 
Several forms of nitric oxide synthase (NOS) are known to exist (Knowles 
and Moncada 1994) which catalyse the formation of nitric oxide (NO) 
from L-arginine (Bredt and Snyder 1989). NO is involved in a number of 
important physiological processes serving both as a neurotransmitter 
and vasodilator (reviewed by Wang et a/1993). Consequently, inhibition 
of NOS leads to vasoconstriction and increased hypoxia (Reviewed by 
Butler et a/1997). The increased hypoxia caused by NOS inhibition has 
prompted Butler and coworker to exploit this phenomenom for the 
activation of bioreductive prodrugs. Indeed, nitro-L-arginine mediated 
inhibition of NOS enhances the bioreductive toxicity of RB 6145 in KHT 
and SCCVII murine tumours (Butler et a/1997). 
However, apart from NOS inhibition, NOS may be able to act as a 
reductase of bioreductive agents itself. The author bases this postulate 
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on the following points. (i) The enzymes are haem based proteins similar 
to members of the CYP family (White and Marietta 1992). (ii) the 
enzymes contain a CPR like domain with binding sites for NADPH, FAD 
and FMN and can be envisaged as a self contained CPR! CYP chimeric 
protein (reviewed by Schmidt et al 1993).and (iii), elevated NOS 
expression has been detected in a number of human tumours, compared 
to normal tissue (Thomsen et a/1994). 
1.6.2 The Cytochrome P450 reductase (CPR)I haem 
oxygenase (HO) system 
'Microsomal haem oxygenases (HOs) are monomeric enzymes which (in 
conjunction with CPR) utilise NADPH and oxygen to oxidise haem to 
biliverdin with the subsequent liberation of carbon monoxide (Abraham 
et al 1988). Biliverdin is broken down further to bilirubin by the action of 
cytosolic biliverdin reductase (Ewing et a/1993). Two HO enzymes are 
known to exist (HO-1 and HO-2) and both are the products of two 
separate genes (Cruse and Maines 1988). Hypoxic conditions, and a 
variety of other environmental stresses, leads to the up regulation of HO-
1 mRNA and, in turn, elevated HO-1 protein (Murphy et al 1991, 
Applegate et al 1991 and reviewed by Choi and Alam 1996). Under 
these conditions, the CPR/ HO system might act as a make shift 
haemoprotein with a reduced potential to oxidise haem (due to a poverty 
of molecular oxygen) but , instead, passing electrons onto another 
electron acceptor molecule such as the nitrogen atom of an N-oxide 
based prodrug. If this scenario did occur, then HO proteins would be 
ideal targets for prodrug therapy as they are highly expressed in a variety 
of neoplastic tissue including Hodgkin's disease (reviewed by Schacter 
1988), squamous carcinomas (Murphy et al 1993) and renal cell 
carcinomas (Goodman et a/1997). 
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1.7 Aims 
From the preceding discussion it is clear that bioreductive activation of 
anti cancer prodrugs is a process dependent on the presence of 
appropriate 'activating' enzymes. The identity of enzymes known to 
mediate the reductive activation of a number of model bioreductives , 
such as the mitomycins and the heterocyclic-N-oxide tirapazamine, have 
been widely published in the scientific literature (reviewed by Workman 
and Stratford 1993). AQ4N, on the other hand, is a novel anthraquinone 
di-N-oxide prodrug due to enter clinical trial in 1998. To date, detailed 
investigations into the enzymatic conversion of AQ4N to its active 
metabolites have not been published. There is, however, evidence that 
rodent cytochrome P450s (CYP) can reductively activate a number of 
model N-oxides (reviewed by Bickel 1969, Sugiura et a/1977 and Powis 
and Wincentsen 1980). With this in mind the aims of the present work 
were: 
1) To investigate the metabolism of AQ4N and its mono-N-oxide AQM in 
rat subcellular fractions, a rich source of enzymes, and determine 
whether rat cytochrome P450 enzymes (CYP) were able to metabolise 
both compounds. Furthermore, preliminary experiments were performed 
to investigate the ability of a recombinant nitric oxide synthase (NOS) 
and the cytochrome P450/haem oxygenase (CPR! HO) enzyme complex 
to bioreduce AQ4N. 
2) To extend the findings of the above to establish whether human CYP 
enzymes were capable of AQ4N and AQM metabolism. Furthermore, 
experiments were performed to determine whether renal and colonic 
human tumours were able to support the metabolism of AQ4N. 
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3) To conduct a preliminary investigation into the in vivo metabolism of 
AQ4N in mice bearing a number of different tumours with a view to (i) 
Identifying metabolites of AQ4N in tumour material and so confirm AQ4N 
metabolism is not restricted to the in vitro setting and (ii) establish 
whether the quantity of AQ4 detected in the tumours correlates with their 
in vivo sensitivity to AQ4N treatment as determined by Cole and co 
workers (1995). 
1.8 Definition of terms 
Throughout the course of this thesis the terms 'metabolism of AQ4N' 
have been used to represent the process shown in Figure 7 and 
summarised in equation \ . 
AQ4N ---il"~ AQM + AQ4 Equation 1. 
Where AQ4N = The anathraquinone di-N-oxide prodrug 
AQM = The two electron reduced mono-N-oxide of AQ4N 
and AQ4 = The fully reduced cytotoxic tertiary amine. 
The termsl total metabolism' or 'total substrate turnover have been used 
and refer to the sum of metabolites (AQM +AQ4) produced following 
incubation of AQ4N with various subcellular fractions. 
Furthermore, where AQM has been used as substrate, the terms 
'metabolism of AQM', 'AQM to AQ41 and/ or 'AQ4 from AQM' refer to the 
process shown in equation '1 
AQM ---II.~ AQ4 Equation 2. 
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Chapter 2 
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Chapter 2 
Materials and methods 
2.1 General Approach used to study the metabolism of AQ4N 
The approach followed in identifying the major bioreductive enzymes of 
AQ4N and AQM was broadly based on enzyme directed methodology as 
described by Workman and Walton (Workman and Walton 1990). Firstly, 
metabolic studies were conducted in rat subcellular fractions under 
various conditions of pH, temperature and various oxygen tensions. The 
results of these experiments would indicate the nature and extent of 
metabolism and help identify the optimum conditions under which AQ4N 
and AQM metabolism occured. Furthermore, preliminary in vitro 
metabolism studies were conducted on the ability of some purified CYP 
related enzyme systems to metabolise AQ4N, namely nitric oxide 
synthase (NOS) and the cytochrome P450 reductase/haem oxygenase 
system (CPRJ HO). 
Secondly, to establish the involvement of CYP's in the metabolism of 
AQ4N and AQM a selection of microsomes prepared from rats pretreated 
with known CYP inducers were incubated with both substrates under 
optimum metabolising conditions. To clarify the findings of these 
experiments incubations were repeated using the general CYP 
inhibitors, carbon monoxide and ketoconazole and chemical, isoform 
specific, inhibitors. The kinetics parameters of AQ4N metabolism in rat 
microsomes, V max and Km , were established by firstly carrying out pre-
kinetic experiments. These experiments were designed to determine at 
what point metabolite production deviated from linearity and hence 
establish a range over which metabolism is first order with respect to time 
and protein concentration. These experiments were conducted at 
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optimum pH, temperature and using saturating substrate and cofactor 
solutions. 
AQ4N and AQM metabolism was investigated in 17 human liver 
microsome preparations which had been pheonotyped with respect to 
their CYP expressions / activities. Correlation analysis was then used to 
determine which CYP's were responsible for the metabolism of both 
substrates. The kinetic data, V max, Km and intrinsic 'clearance CLint for 
three individual livers was determined using a similar protocol to that 
used for the rat. The CYP involvement in metabolism of AQ4N was then 
confirmed by the use of isoform specific inhibitors and the use of 
microsomes prepared from human Iymphoblastoid cell lines transfected 
with a vector insert carrying a cDNA specific for a single CYP. Basic 
metabolism experiments were then carried out in a variety of human 
normal and paired neoplastic tissue, along with experiments using 
carbon monoxide as a general CYP inhibitor to ascertain the involvement 
of CYP in any metabolism observed. 
Finally, the in vivo metabolism of AQ4N was investigated in tumour and 
non tumour bearing rodents. AQ4N was given i.p. to the animals and, 
following animal sacrifice, tissues were removed and assayed for the 
presence of AQ4N and its metabolites. 
2.2 Chemicals 
Chemicals used were obtained from the following sources: All standard 
laboratory reagents were purchased as the highest commercially 
available grade and obtained from BDH Ltd, Poole, UK. 1,4-Bis-{[2-( 
dimethylamino-N-oxide)ethyl]amino}-5,8-dihydroxy-anthracene-9, 1 0-
dione (AQ4N), 1,_{[2_(dimethylamino-N-oxide)ethyl]amino}-4-{[2-[ 
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dimethylamino]ethyl]amino}-S,8-dihydroxyanthracene_9,1 O-dione (AQM) 
and 1,4-Bis-{[2-( dimethylamino )ethyl]amino }-S,8-dihydroxy-anthracene-
9,10 dione (AQ4) were synthesised in house by Mr K. Ruparelia and 
shown to be pure and authentic by HPLC, MS, NMR and elemental 
analysis. Benzoxylresorufin and Diethylthiocarbamate (DIE) were both 
obtained from Aldrich, Ltd, Dorset, UK. Clofibrate (CLO), haemin, 
isoniazid (ISO), ketoconazole (KET), 3-methylcholanthrene (3MC), 
metyrapone (MEn, reduced nicotinamide adenine dinucleotide (NADH), 
olive oil (00), phenobarbitone (PB), pregnenolone-16alpha-carbonitrile 
(PCN), Triacetyloleandomycin (TAO), and Tween 80 (TWE), were all 
obtained from Sigma Ltd, St Louis, USA. Nicotinamide adenine 
dinucleotide phosphate (NADPH) was obtained as the tetra sodium salt 
from Park Scientific Ltd. Ethylenediamine tetra acetic acid (EDT A) was 
obtained from BDH Ltd, Poole, UK. Bromophenol blue, Dithiothreitol, 
glycine, sodium dodecyl sulphate (SDS), TEMED, and TRIS 
(hydroxymethylaminomethane) were all obtained from Biorad 
Laboratories, CA, USA 
2.2.1 Human tissue acquisition. 
Human livers were kindly provided by Professor M Danny Burke. 
Permission having previously been obtained from the Joint Ethics 
Committee of Aberdeen University and Aberdeen Royal Hospital NHS 
Trust. Livers, from either road accident victims or organ donor patients 
were removed within 30 min of circulatory arrest, placed in ice cold 
isotonic saline and cut into 2 x 2 x 4 cm pieces before being stored at - 80 
°C. All samples had previously been screened for hepatitis Band HIV 
infection and found to be negative for both. Kidney and colon samples 
from patients having undergone surgical resection for a number of 
neoplasms, along with samples of normal tissue resected from the same 
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patients, were provided from Dr G I Murray, Department of Pathology, 
Aberdeen University, UK. The clinical data associated with the human 
liver microsome preparations and the human tumours are shown in 
tables 2 and 3 respectively. Gloves were used when handling human 
tissue and at the end of experiments all work surfaces and other 
equipment were washed in Viron disinfectant. (Antec Ltd, Sudbury, UK). 
Table 2 Characteristics of human livers used. 
t Smoking is classed as either nil, minor (:::; 5 cigarettes per day) or major 
(:::; 6 cigarettes per day).* Alcohol consumption is classed as either nil, 
minor (social or occasional drinker) or major (regular or heavy drinker) 
. Sample 
HLM26 
HLM29 
HLM32 
HLM33 
HLM34 
HLM35 
HLM 36 
HLM38 
HLM44 
HLM45 
HLM47 
HLM48 
HLM50 
HLM52 
HLM53 
HLM54 
HLM55 
Age Sex 
55 F 
63 F 
66 F 
47 F 
41 F 
No information 
39 F 
53 F 
44 F 
21 M 
22 F 
31 M 
37 M 
48 M 
38 M 
58 M 
60 M 
Drug history(Smoking!/ Alcohol*) 
Moderate alcohol/ Nil smoker. 
Minor alcohol/ No information. 
Moderate alcohol/ Heayy smoker. 
Moderate alcohol! No information. 
Moderate alcohol/ Heavy Smoker. 
No information. 
Minor alcohol/ Heavy smoker. 
Nil alcohol/ Nil smoker. 
Moderate alcohol/ Heavy smoker. 
Major alcohol/ Medium smoker. 
Moderate alcohol/ Heavy smoker. 
No information/ No information. 
Major alcohol/ Heavy smoker. 
Major alcohol! Heavy smoker. 
Major alcohol! Heavy smoker. 
Major alcohol/ Heavy smoker. 
Moderate alcohol/ Ex smoker. 
Table 3 Characteristics of human normal and neoplastic tissue used. 
Sample and ID Age/Sex Type of Tumour 
Kidney/ HKT 5 621M Clear cell carcinoma 
Kidney/ HNK 5 " Paired normal tissue from HKT 5 
Kidney/ HKT 6 65/ F Clear cell carcinoma 
Kidney/ HNK 6 " Paired normal tissue from HKT 6 
Colon/HCT 4 66/ F Adenocarcinoma 
ColonlHNC4 " Paired normal tissue from HCT 4 
ColonlHCT 5 521 F Adenocarci noma 
Colonl HNC 5 " Paired normal tissue from HCT 5 
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2.2.2 Enzymes and transfected cell microsomes 
Lymphoblastoid cell microsomes (10 mgl mL ) expressing CYP 3A4,CYP 
2B6, control and CPR were obtained from Gentest Inc. (Woburn, MA, 
USA). The individual microsome preparations were prepared by cDNA 
mediated gene transfection into recipient b- Iympohoblastoid cells (AHH-
1 TK± cell lines) as described by Crespi et al {1993). Microsomes were 
provided with the following marker activities of CYP as documented in 
the manufacturers literature: CYP 2B6 (360 pmole/min/mg of 7-ethoxy- 4-
trifluoromethylcoumarin deethylation) and CYP 3A4 (2020 pmole/min/mg 
of testosterone 6 beta-hydroxylation). The activities of transfected 
microsomes bearing the cytochrome P450 reductase and CYP 3A inserts 
are described in section 2.9.2. Haem oxygenase protein (HO- 1) was the 
gift of Professor Ortiz de Montellano (The University of California, San 
Francisco, USA). The enzyme provided was a truncated form of the 
human HO-1 protein. In essence, a DNA sequence without the bases 
coding the terminal 23 amino acids was constructed in the pBAce vector 
and expressed in E. coli. The purification and activity of this protein has 
been described in detail by Wilks and Ortiz de Montellano (Wilks and 
Ortiz de Montellano 1993). Recombinant rat brain nitric oxide synthase 
(nNOS) was provided by Dr V Riveros- Moreno (Wellcome Research 
Laboratories, Beckenham, UK). The enzyme was expressed in the 
baculovirus system (Charles et al 1993), and purified by the method 
described by Riveros- Moreno et al (1995). Rat cytochrome P450 
reductase (CPR) was provided by Professor C R Wolf (Molecular 
Pharmacology Unit, Ninewells Hospital and Medical School, Dundee, 
UK). Molecular mass markers (range: 14- 70 KDa) were obtained as pre 
made mixtures from The Sigma chemical Company, St Louis, MO, USA. 
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2.3 Animal inducer treatments 
Male Sprague Dawley (200-250 g) rats were housed in standard 
laboratory cages and allowed free access to food and water before the 
following treatments were started. 
2.3 1 Phenobarbitone (PB) an inducer of CYP 2B (Guengerich et al 
1982): Rats were given a 0.1% (w I v) solution of sodium phenobarbitone 
(BDH) in drinking water for 6 days followed by a day of rest with normal 
drinking water before being killed. 
2.3.2 Clofibrate (CLO) an inducer of CYP 4A (Sundseth and Waxman 
1992): clofibrate (Sigma) was administered (Lp.) at a concentration of 
200 mg I kg of body weight dissolved in 0.5 mL of 2.5% tween 80 once a 
day for 4 days prior to 1 day of rest before being killed. CYP 4A inducer 
2.3.3 Pregnenolone 16alpha-carbonitrile (PCN) an inducer of CYP 3A: 
(reviewed by Murray and Reidy 1990): Rats were given a 5% (w/v) 
solution of PCN (Sigma), approximately 50 mg dissolved in 0.5 mL of 
2.5% tween 80 (Sigma) once a day for 4 days prior to 1 day of rest prior 
to being killed. 
2.3.4 Isoniazid (ISO) an inducer of CYP 2E (Ryan et a/1985): Rats were 
given 0.1 % isonicotinic acid hydrazide (Sigma) (w Iv) dissolved in 
drinking water ad libitum for 10 days, followed by a day of normal 
drinking water, before being killed. 
2.3.5 3-Methylcholanthrene (3 MC) an inducer of CYP 1 A (Ryan et al 
1979): Rats were given 2 mL of 1 % (w/v) 3 MC (approximately 80 mg I kg 
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body weight) dissolved in olive oil (Sigma) by i P injection and killed 72 
hours later. 
2.3.6 Inducer controls. Rats were treated in an identical manner to 
treated animals but given the injection vehicle minus the inducing agent. 
Specifically, controls for PCN and CLO treated rats were given 0.5 mL of 
2.5% tween 80 (TWN ) once a day for 4 days prior to 1 day of rest before 
being killed. Controls for MC treated rats were given 2 mL of olive oil ( 
00 ) by Lp injection and killed 72 hours later. 
2.3.7 Untreated controls (UT): Controls for PB and ISO treated rats. Rats 
were given free access to food and water ad libitum before being killed 
The above rat induction treatments were conducted at The Department of Biomedical 
SCiences, University of Aberdeen, Aberdeen UK. The induction methods are described 
by Weaver et a/1995. 
2.4 Preparation of tissue fractions. 
Human tissue was removed from the - 80° freezer, thawed on ice and 
rinsed in a solution of ice cold 1.150/0 KCI in 0.01 M Tris buffer pH7.6. For 
animal studies, male Spague Dawley rats weighing 200-250g were 
obtained from Charles River Ltd, Margate, Kent UK. After appropriate 
inducer treatment, as outlined above, animals were killed by cervical 
dislocation and the livers rinsed in the ice cold rinse solution mentioned 
above. Livers from either human or rat were blotted dry, placed in a 
solution of ice cold 0.1 M Tris buffer pH 7.4 and cut into small pieces by 
immersing scissors into the suspension of buffered liver. The following 
procedures were then carried out on ice and all centrifuge tubes/ 
homogenising equipment were precooled before use. 
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All ice cold buffered tissue was homogenised using an Ultra Turax 
automated homogeniser at low speed (Type 1S/2, Janke and Kundel, 
Germany), in order to prevent enzyme denaturation. Homogenised 
samples were then placed in ice cold 13.5 mL plastic centrifuge tubes 
(Nalgene Ltd, Rochester, New York USA) and weighed using a pan 
balance (Mettler Ltd Switzerland). All samples were then placed in a 
refrigerated preparative centrifuge (Beckmann Ltd, UK) and centrifuged 
at 12500 g (13500 rpm) in a 50 Ti rotor for 20 minutes at 4°C. 
The sample supernatants obtained from this initial spin were then poured 
into fresh ice cold centrifuge tubes, re weighed and centrifuged at 100 
000 g (40 000 rpm) for 60 minutes at 4°C. The crude microsomal 
fractions obtained were then resuspended in ice cold 0.1 M Tris buffer / 
1 mM EDTA containing 150/0 glycerol v/v pH 7.4 placed in clean, ice cold 
centrifuge tubes and centrifuged (washed) at 100 000 g for a further 60 
minutes at 4°C. The supernatants obtained from this second 100 000 9 
spin were carefully decanted into 1 .5mL eppendorf tubes and stored at 
-SO°C. The washed microsomal pellets were re suspended in an ice cold 
solution of 0.01 M Tris buffer 1 1 mM EDTA containing 15% glycerol v/v pH 
7.4, aliquoted into 1.5 mL eppendorf tubes and stored at - SO°C prior to 
use. 
2.5. Protein quantitation. 
Total tissue protein was determined by the use of a modified Bradford 
assay (Bradford 1976) using a Biorad kit. Briefly, a standard curve of 
bovine serum albumin (BSA) was prepared in 0.1 M sodium 1 potassium 
phosphate buffer pH 7.6 to cover a concentration range of 0 to 1 mg / mL 
BSA. The absorbance of the standard curve was then measured at 595 
nm using a Perkin Elmer lambda 16 spectrophotometer. Following this 
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the absorbance and protein concentration of unknown samples was 
determined by reference to a standard curve. 
2.6. Reagent degassing and hypoxic conditions 
Anaerobic metabolism was performed in a steel glove box fitted with a 
transparent perspex top (Gallenkamp Ltd). All reagents including: 
incubation buffer (0.1 M sodium/potassium phosphate buffer, pH 7.6), 
and 1 mM stock solutions of AQ4N and AQM were adjusted to the 
desired 0/002 by bubbling each solution with oxygen free nitrogen or air 
(SDH Ltd). All equipment needed for a metabolism experiment were 
then transferred to the glove box. The glove box and contents were then 
sealed by the use of an arm length pair of rubber gloves (SDH Ltd). 
Finally the interior of the glove box was made hypoxic by allowing 
oxygen-free nitrogen to pass into the chamber at a flow rate of 1-2 L per 
min. The 0/002 was monitored throughout the course of an experiment by 
the use of a model 781 oxygen meter (Strathkelvin Instruments Ltd) fitted 
with an E5 oxygen electrode (Uniprobe Instuments Ltd). The oxygen 
meter was calibrated as described in the manufacturers instructions 
2.7. Metabolism of AQ4N and AQM in subcellular fractions. 
Aliquots of rat or human microsomes or cytosol were removed from the 
-80°C freezer and allowed to thaw at 37°C in a temperature block (Grant 
Instruments Ltd). Upon thawing samples were stored on ice and 
transferred to the steel glove box in preparation for a metabolism 
experiment. In a typical metabolism experiment, degassed 0.1 M sodium 
/ potassium phosphate buffer (pH 7.6) was pre-warmed with a solution of 
NADPH (4mM) for a period of 5 min in a Grant temperature block at 37°C. 
Microsomal protein (100- 400 Jlgs) was then added to the incubate and 
allowed to warm for another 5 minutes. Finally, 100 JlM AQ4N or 100 JlM 
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AQM was added to the incubation mixture, to initiate reaction, giving a 
final incubation volume of 250 Jll, Tubes were then mixed by three 
inversions and rapidly replaced in the temperature block to allow 
metabolism. In anaerobic experiments the oxygen content of all reagents 
and the interior of the glove box never exceeded a value of 0.5%. This 
was achieved as described in section 2.6. For single time point 
metabolism, the reaction mixture was quenched by the addition of an 
equal volume of ice cold 50% acetonitrile / 50% (v/v) water adjusted to 
pH 2.0 using several drops of a 10M solution of Hel followed by placing 
in ice. Using an appropriate modification of the above procedure, the 
effect of protein concentration, cofactor addition, pH, temperature, time, 
substrate concentration, and %02 on metabolism were determined. 
Metabolic incubations were carried out in triplicate and expressed as 
mean metabolite formed I mg protein / minute ±SE unless otherwise 
stated. Metabolism of AQ4N was investigated also in human normal and 
neoplastic kidney and colon. These incubations were conducted in an 
identical manner to that outlined above but 800 Jlg of protein were used 
with an appropriate adjustment of incubation buffer to maintain the 
incubation volume at 250 JlL. Control reactions for each tissue type 
investigated included incubates minus NADPH, incubates plus air, 
incubates minus microsomes or cytosol and incubates plus heat 
denatured microsomes. 
2.7.1 Effect of inhibitor addition on metabolism 
Inhibition studies were conducted using a modified method of the basic 
metabolism studies. In brief, ketoconazole (KET) at a final concentration 
of 100 JlM, used as a general CYP inhibitor (Ervine et a/1995, Sequeira 
and Strobel 1996 and Dushkin et al 1995), and alpha-naphthoflavone 
(ANF) at a final concentration of 10 JlM used as an inhibitor of CYP's 1 A 1, 
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1 A2, 2CB and 2C9 (Chang et a/1994) were both dissolved in ethanol 
and evaporated to dryness at 37°C. Triacetyloleandomycin (TAO; final 
concentration 50 JlM) an inhibitor of CYP's 3A3, 3A4 and 3A5 (Chang et 
gL 1994) and metyrapone (MET; final concentration of 10 JlM and 1 JlM) 
an inhibitor of CYP 2B 1 (Adeagbo 1997) were both dissolved in DMSO. 
Diethyldithiocarbamate (DIE) used at a final concentration of 30 JlM as an 
inhibitor of CYP's 2A6 and 2E1 (Onos et a/1996) was dissolved in water. 
All metabolic incubations followed the method described earlier apart 
from experiments using TAO, and MET where a pre incubation time of 10 
minutes was allowed for mechanism based inactivation of CYP's before 
'adding substrate. Control incubations were treated in an identical 
manner but using DMSO in place of inhibitor. Carbon monoxide (CO) 
was bubbled into prewarmed anaerobic incubates at an approximate 
rate of one bubble per second for a period of two minutes prior to 
substrate addition. 
2.7.2 Oxidative metabolism of AQ4. 
The oxidative metabolism of AQ4 was investigated in rat and human 
subcellular fractions using the following method. For rat experiments, 
200 Jlg of microsomal protein and cytosol were added to air saturated 
0.1 M sodium/potassium phosphate buffer (pH 7.6) containing 4mM 
NADPH and 50 Jll DMSO and prewarmed for 10 minutes at 37°C in an 
incubation chamber (Stuart Scientific ltd). Reaction was initiated by the 
addition of AQ4 to give a final concentration of 100 JlM in a total reaction 
volume of 1 mL. The effect of ketoconazole on metabolism was 
determined in separate incubations by replacing the 50 Jll DMSO with 
an equivalent volume of 2 mM ketoconazole to give an inhibitor 
concentration of 100 JlM. All incubations were carried out in open glass 
vials and reactions were terminated after 60 min by the addition of 1 ml 
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of 50% acetonitrile/ 50% water. For human hepatic studies, the above 
procedure was followed but 400 J.lg of microsomes and/or cytosol were 
used. Oxidative metabolism of AQ4 was investigated in liver 
preparations 10 47 and 10 55. All results were expressed as the mean of 
two incubations. Control reactions consisted of aerobic incubates minus 
NAOPH, aerobic incubates depleted of microsomes and aerobic 
incubates plus heat denatured microsomes. Furthermore, the 
metabolism of AQ4 was investigated under conditions of hypoxia as 
described in section 2.6. All control incubations were carried out in 
duplicate for both rat and human subcellular fractions. 
2.7.3 Kinetic analysis 
The kinetic data from at least six substrate concentrations (10-200 J.lM) 
versus initial reaction velocity were simultaneously fitted to the Michaelis 
_ Menten and Hill equations, equations 3 and 4- below. Hanes- Woolf 
transforms ([S]/v versus [8]) were used to (1) confirm the calculated 
values for Km and V max and (2) expose any deviation from Michaelis-
Menten behaviour. All operations were performed on a Macintosh IIci 
computer running Ultrafit (2.0) kinetic software (Biosoft, Cambridge, UK). 
v = V max [S] / Km + [8] Equation 3 
Where v = initial reaction velocity, Vmax = maximum reaction velocity, Km 
= the Michaelis constant (concentration at which reaction velocity is half 
maximal) and 8 = substrate concentration. 
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v = Vmax [S]n / Km + [S]n Equation 4. 
where n = the Hill coefficient (equivalent to the number of substrate 
binding sites). 
2.8. SDS PAGE 
Protein samples diluted to a concentration of 0.25 mgt mL from a stock 
solution of sample buffer comprising of: 1 mL 0.5 M TRIS- HCI (pH 6.8), 
glycerol (10% v/ v), SOS (2% wi v), dithiothreitol (1.5% wi v) and 
bromophenol blue (0.05% wi v) in a total volume of 8 mL, were boiled for 
5 min along with a sample of preprepared molecular mass markers 
(Sigma Ltd). Protein samples (3 f.Lg of HO-1 and 4 f.Lg CPR) as well as 4 
flL of molecular mass markers were then carefully loaded on to two 
separate stacking gels (10% acrylamide) supported by two different 
separating gels comprising of: 12% acrylamide for HO-1 and 7.5% 
acrylamide for CPR. Both gels were placed upright in a mini protean II 
unit (Biorad Ltd), and covered with 300 mL of running buffer comprising 
of: TRIS (3 g/ L) and glycine (14.4 gI L). The complete gel assembly was 
then connected to a Biorad power box and both gels were run at 200 V 
for 45 min at room temperature. Protein bands were subsequently 
identified by the use of a Biorad Silverstain plus kit. 
2.8.1 Haem Oxygenase 1 (HO- 1) activity 
HO- 1 activity was measured by the linear increase in absorption 
(bilirubin formation) at 468 nm in an assay containing 0.1 M 
sodium/potassium phosphate buffer (pH 7.6) pre incubated for 5 min at 
37°C with 12.5 f.Lg HO-1, 80 f.Lg CPR, 30 f.LM haemin and 100 f.LL rat 
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cytosol (source of biliverdin reductase). The reaction was initiated by the 
addition of NADPH to a final concentration of 100 J.1M. The total reaction 
volume was 1 mL. 
2.8.2 Metabolism of AQ4N using the CPR I HO-1 system* 
Incubations consisted of 0.1 M sodium/potassium phosphate buffer (pH 
7.6) pre incubated under hypoxic conditions at 37°C for 5 min with 1.5 J.1g 
of CPR (equivalent activity to 0.003 J.1mol cytochrome c reduction/min), 
7.5 fl9 of HO-1 (equivalent activity to 0.7 nmol/min bilirubin formation) 40 
J.1M haemin and NADPH (to give a final concentration of 200 J.1M). 
Reaction was initiated by the addition of AQ4N to give a final 
concentration of 100 flM in a total reaction volume of 100 J.1L. Control 
incubations consisted of the above mixture minus the HO-1 protein. 
Additional controls consisted of the mixture minus HO-1 run separately in 
the absence of a) NADPH b) haemin and c) CPR. Aerobic metabolism 
was also investigated in both mixtures (with and without HO-1 protein) 
using air saturated 0.1 M sodium/potassium phosphate buffer in open 
eppendorf tubes. Reactions were terminated after 120 min of incubation 
by the addition of 100 flL of 50% acetonitrile/ 500/0 water. Samples were 
processed and metabolites detected and quantified by the method 
described in section 2.9. 
*The incubations using the CPR/ HO system were performed by Miss P. Tein, 
Department of Pharmaceutical Sciences, De Montfort University, Leicester. 
2.8.3 BROD, Cytochrome P450 reductase (CPR) and nitric 
oxide synthase (nNOS) activities. 
The benzoxyl O-deethylation (BROD) reaction was performed under 
yellow light, by a method modified from Burke et a/1985, using a Perkin 
Elmer 3000 fluorescence spectrophotometer. Each assay consisted of: 
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transfected cell microsomes (20 J.lL of 10 mg/mL) pre incubated in 0.1 M 
sodium/potassium phosphate buffer (pH 7.6) at 37°C for 10 min with 
NADPH (250 J.lM in final incubation volume) and 5 J.lL DMSO. Reaction 
was initiated by the addition of 5 J.lL of benzoxyl resorufin to give a final 
concentration of 0.05 mM and the total reaction volume was 1 mL. The 
linear formation of the fluorescent metabolite was monitored at excitation 
and emission wavelengths of 530 nm and 585 nm respectively. 
Quantitation was achieved by addition of 0.025 nmol of authentic 
resorufin to the reaction cuvette. The effect of the CYP 3A inhibitor TAO 
was determined by replacing the DMSO in the pre incubation step with 5 
J.lL of TAO giving a final inhibitor concentration of 50 J.LM. 
The activity of cytochrome P450 reductase (CPR) in human 
Iymphoblastoid cell microsomes was measured with a Perkin Elmer 
spectrophotometer using a modification of the method provided in the 
manufacturers literature. Specifically, an NADPH generating system 
consisting of: NADP+ (1.3 mM) , glucose-6-phosphate (3.3 mM) glucose-
6-phosphate dehydrogenase (0.4 U/ mL), magnesium chloride (3.3 mM) 
and 0.95 mg/mL oxidised horse heart cytochrome C were all 
preincubated in 0.1 M sodium phosphate buffer (pH 7.6) at 37°C for 5 
min. The reaction was initiated by the addition of 25 J.lL of transfected 
microsomes (giving a final a final concentration of 0.25 mg/mL) to the 
sample cuvette and 25 J.lL of 0.1 M sodium / potassium phosphate buffer 
(pH 7.6) was simultaneously added to the reference cuvette, giving a 
final volume of 1 mL in both cuvettes. The linear increase in cytochrome 
C reduction was monitored at 550 nm and CPR activity was calculated 
using a millimolar extinction coefficient of 19.6 m~1 cm-1.(Gibson and 
Skett 1994). Semi purified CPR activity was measured as described 
above using 1.5 J.Lg of semi purified enzyme (2 J.LL) in place of transfected 
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microsomes. The reaction was initiated by the addition of NADPH to a 
final concentration of 100 11M in place of the NADPH generating system. 
nNOS activity was measured by cytochrome c reduction ( reviewed by 
Schmidt et a/1993) using 3 J,l9 of the enzyme (3 Ill) pre warmed in 0.1 M 
sodium/ potassium phosphate buffer (pH 7.6) and 5 mgt ml cytochrome 
c. The reaction was started by the addition of NADPH to a final 
concentration of 100 J,lM in a total incubation volume of 1 mL. The 
reduction of cytochrome c was measured and calculated in an identical 
manner to that described above. 
2.8 4 Metabolism of AQ4N using purified rat brain nitric oxide 
synthase (nNOS). 
Incubations consisted 5J,ll of nNOS and NADPH (200 11M final 
concentration preincubated under hypoxic conditions in 0.1 M 
sodium/potassium phosphate buffer (pH 7.6) at 37°e for a period of 5 min 
before the addition of AQ4N to a final concentration of 500 J,lM. The total 
reaction volume was 200 J,ll and metabolism was terminated after a 
period of 120 min by the addition of ice cold 200 III of 50% acetonitrile/ 
50% water. Control incubations were performed in the absence of 
NADPH and nNOS. Aerobic metabolism was also investigated using 
identical conditions to the anaerobic incubations but using air saturated 
buffer in open eppendorf tubes. Metabolites were detected and 
quantified by the method described in section 2.9. 
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2.8.5 Metabolism of AQ4N in human Iymphoblastoid cell 
microsomes expressing CYP 3A4, control, CYP 286, and 
cytochrome P450 reductase (CPR) 
Metabolism of AQ4N in the transfected microsomes was carried out in a 
similar fashion to the metabolism experiments described in section 2.6. 
In brief, incubations consisted of 40 Jll of 10 mg/ml microsomes pre 
incubated for 5 min at 37°C in 0.1 M sodium phosphate buffer (pH 7.6) 
containing 20 J..ll of NADPH (4 mM of final incubation volume). Reductive 
metabolism was initiated by the addition of AQ4N to a final concentration 
of 100 J..lM in a total reaction volume of 250 JlL. Reactions were 
terminated by the addition of an equal volume of ice cold 50% 
acetonitrile / 50% water adjusted to pH 2.0 using several drops of a 10M 
solution of HCI followed by placing on ice. 
2.9. Deproteinisation, HPLC, metabolite detection and 
quantitation 
After the termination of metabolism samples were deproteinised by 
centrifugation at 6 000 rpm for 5 min using a Jouan benchtop 
centrifuge. Sample supernatants were then removed for HPlC analysis. 
AQ4N and the two metabolites AQM and AQ4 were resolved isocratically 
using a 3.9 x 2.0 cm sentry guard cartridge mounted in a Waters steel 
sentry guard cartridge holder immediately followed by a Novopak ( 4 Jlm 
) 3.9 x 15 cm C8 analytical column. Samples were delivered via a 
Waters 510 pump and 712 wisp in a mobile phase consisting of 80% 0.5 
M ammonium formate /20% acetonitrile (pH 4.2) at a constant flow rate 
of 1 mUmin. The injection syringe was automatically purged in methanol 
between each sample injection to prevent sample carry over. At 635 nm, 
the lambda max for all three compounds, AQ4N, AQM and AQ4 have 
approximate retention times of 10.5, 7.6 and 5.5 minutes respectively. 
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The authenticity of each peak was confirmed by continually monitoring 
the visible spectrum from SOO nm to 700 nm using a Waters 994 
photodiode array detector for the duration of each chromatographic run. 
In experiments using purified CPR! haem oxygenase-1, AQ4N and its 
metabolites were detected in an identical manner to the above procedure 
using a modified mobile phase which consisted of: 5mM 1-
heptanesulphonic acid, triethanolamine (2%), formic acid (0.7%) and 
acetonitrile (30%). Using these conditions AQ4N and AQ4 were shown 
to have retention times of 6.6 and 3.8 min respectively*. Quantitation was 
achieved by automated AUC determination using an NEC powermate 
486 / 66i computer running millennium 2.10 chromatographic software 
and subsequent extrapolation to a standard curve. Standard curves 
were constructed in triplicate using authentic compounds synthesised in 
our laboratory prepared in incubation buffer containing an appropriate 
amount of tissue protein followed by dilution in 50% acetonitrile / 50% 
water. Standards were deproteinised and injected into the HPLC system 
in an identical manner to test samples. The recovery of AQ4 and AQM 
after deproteinisation was checked against standard curves prepared in 
a similar manner but minus tissue protein. Within run and between day 
coefficients of variation (CVs) were checked by comparing the AUC for 
independently processed, but identical concentrations of AQ4 and AQM. 
The stability of buffered AQ4, AQM and AQ4N was checked by preparing 
and storing stock concentrations of each compound at 4°C followed by 
HPLC analysis to detect any significant breakdown of compound as a 
function of time. 
* Detection of metabolites from the experiment using the CPR / HO-1 system was 
conducted by Miss P. Tien. 
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2.9 1 Correlation analysis 
Non-parametric Spearman rank Correlation analysis between the 
metabolism of both substrates (AQ4N and AQM) and various CYP 
activities were based on the markers listed in table 4. Data for each CYP 
activity were collected by several members of the CYP research group, 
headed by Professor M D Burke at Aberdeen University and Spearman 
coefficients (r s) were generated by the use of an Macintosh IIci computer 
running Statview II software. Significance was determined as described 
in section 2.9.2. 
Table 4. Markers used for CYP activity 
CYP CYP marker Reference (activityonl~) 
CYP3A Benzoxylresorufin O-deethylation Burke et a/1994 
CYP3A Tamoxifen N-demethylation Crewe et a/1997 
CYP2C Tolbutamide hydroxylation Nedelcheva and G ut1994 
CYP2C Anti- CYP 2C antibody 
CYP1A Anti- CYP 1 A antibody 
CYP2A Coumarin 7 -Hydroxylation Yun et a/1991 
CYP2D Dextromethorphan O-demethylation Dayer et a/1988 
Anti- CYP 1 A and 2C antibodies were used to detect CYPs 1 A and 2C apoprotein by 
western blotting. Blots were conducted by members of the CYP research group at 
Aberdeen Univesity. Benzoxylresorufin O-deethylase activity was conducted by Mr 
E.Wanogho by a modified method to that decribed by Burke et a/1985. Tolbutamide 
hydroxylation and Tamoxifen N- demethylation were conducted by Dr R Weaver and Mary 
Maley respectively using appropriate modifications of the methods decribed by Miners et 
a/1988 and Jacolot et a'-1991. Coumarin 7-hydroxylase activity was conducted by 
Duncan Webster by a modification of the method described by Miles et a/ (Miles et al 
1990). 
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2.9.2 Statistical analysis 
Significance was determined by the use of an Macintosh Ilci computer 
running Statview II software. Data were subjected to a paired two tailed 
Studenfs t- test. The null hypothesis was rejected at p< 0.05 
2.9.3 Preliminary characterisation of in vivo metabolism of 
AQ4N in tumour bearing mice. 
C3H female and male nude mice were used to determine the in vivo 
metabolism of AQ4N in a variety of rodent and human tumour xenografts. 
Mice (C3H females, 15 per group, bearing RIF- 1 fibrosarcomas, KHT 
fibrosarcomas, and SCCV11 carcinomas) along with 15 nude males 
bearing HT29 human tumour xenografts and a non tumour bearing 
control group (15 C3H females) were all kept in standard laboratory 
cages and allowed free access to food and water. When tumours 
reached an approximate diameter of 7 mm each mouse was given an 
intraperitoneal dose of AQ4N (250 mg/kg, 0.5 mU 25 g mouse body wt in 
PBS). At 15 minutes, 1 hr, 24 hr and 48 hr three mice from each tumour 
group, including the non tumour control group, were sacraficed and 
samples of plasma, tumour, liver, hind leg muscle and gall bladder were 
snap frozen in liquid nitrogen. The tissues were then taken for the 
analysis of AQ4N and its metabolites. 
2.9.4 Drug and metabolite extraction 
Tissue samples were removed from liquid nitrogen and allowed to thaw. 
Each sample of tumour, liver, gall bladder and muscle were then 
homogenised, by the method described in section 2.4, in a small enough 
volume of 0.1 M sodium/potassium phosphate buffer (pH 7.6) to produce 
an approximate 500/0 (w/v) homogenate. Aliquots of plasma were used 
without any buffer addition or homogenisation. An equal volume of water 
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saturated butanol was then added to the homogenate followed by 
shaking. Each sample was then vacuum dried at 45 °C by the use of a 
Vac- drier (PLS Ltd). The blue residue was then re suspended in 50 JlL 
of a solution comprising: 0.5 M ammonium formate/ acetonitrile (70:30 
v/v) , pH 4.2. AQ4N and metabolites were then detected as described in 
section 2.9. Drug and metabolite recovery were checked by spiking 
appropriate tissue homogenates with a known concentration of authentic 
compound and comparing it to an identical concentration made up in 0.1 
M sodium / potassium phosphate buffer (pH 7.6). 
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Chapter 3 
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Chapter 3 
Metabolism of AQ4N and AQM in rat subcellular fractions and 
by purified enzymes 
3.1 Aims 
To investigate the metabolism of AQ4N and AQM in rat subcellular 
fractions and to establish whether prodrug AQ4N and its mono-N-oxide 
AQM are both substrates for hepatic CYP. A second aim was to perform 
preliminary investigations into the ability of some CYP related enzymes 
to mediate AQ4N bioactivation. 
3.2 Materials and methods 
The general approach used in identifying and characterising the 
enzymes involved in the metabolism of both compounds has been 
outlined in chapter 2, section 2.1. All reagents were obtained from the 
sources detailed in section 2.2. 
3.2.2 Animal pre treatment and tissue fractionation 
Male Sprague-Dawley rats (Charles River, Margate, UK), were subjected 
to CYP induction experiments as outlined in section 2.3. Microsomes 
and cytosol were prepared as described in section 2.4 and protein was 
quantified as described in section 2.5. 
3.2.3 Metabolism studies using rat subcellular fractions and 
the use of CYP specific inhibitors 
Assay conditions with regard to the anaerobic conditions of buffers, 
substrates and the interior of the steel glove box used for metabolism 
were as described in section 2.6. In addition, 02 tension was kept at a 
level which never exceeded 0.5% that of atmospheric 02 levels for the 
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duration of each experiment unless otherwise stated. The metabolism of 
AQ4N and AQ4 by rat microsomes and cytosol was based on the method 
outlined in section 2.7. CYP specific inhibitors were preincubated with 
microsomes and either AQ4N or AQM again as described in section 
2.7. 1 and oxidative metabolism of AQ4 was investigated as described in 
section 2.7.2. 
3.2.4 Metabolism studies using the CPR! HO system and rat 
nNOS 
Purified nNOS, HO and partially purified CPR were obtained from the 
sources cited in section 2.2.2 and activity of these enzymes was 
determined as described in section 2.8.1 and 2.8.3. The anaerobic 
metabolism of AQ4N by each of these enzyme preparations has been 
described in sections 2.8.2 and 2.8.4. 
3.2.5 Chromatography and metabolite detection 
The HPLC method used for detection of AQ4N and its two metabolites 
AQM and AQ4 is' described in section 2.9. Analytical variables were 
determined by the procedures described in the same section. 
3.2.6 Kinetic analysis and statistical significance 
Untransformed kinetic data were subjected to the observer independent 
analysis outlined in section 2.7.3. Statistical significance was 
established as previously described in section 2.9.2. Probability values 
of <0.05 were considered statistically significant. 
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3.3 Results 
3.3 1 Chromatography 
Typical standard curves for AQM and AQ4 along with HPLC 
chromatograms are shown in figures 11 and 12 respectively Standard 
curves were constructed in triplicate and prepared by spiking drug free 
tissue samples (of appropriate protein concentration) with varying 
amounts of authentic metabolites. Drug recovery, after protein 
precipitation was consistently ~ 85%) compared to metabolite standards 
made up in the absence of tissue. Within-run and between-run 
. coefficients of variation (CVs) never exceeded a value of 11 % for either 
AQM or AQ4 over a concentration range of 0- 25 nmole. Furthermore, 
due to automated syringe washing in methanol at the end of each 
injection, compound carry over was undetectable. 
3.3 2 Metabolism of AQ4N and AQM in rat hepatic tissue 
In rat hepatic tissue the metabolism of AQ4N yielded two 
chromatographically distinct metabolites identified, by reference to 
authentic compounds, as AQM and AQ4. In experiments using AQM as 
the substrate a single metabolite, AQ4, was detected. AQ4N was 
metabolised at physiological temperature and pH (Figs 13 and 14 
respectively) and the metabolism of both compounds was inhibited by air 
(Figs 15 and 16) and carbon monoxide. Furthermore, the anaerobic 
metabolism of both compounds showed a marked preference for 
NADPH over NADH as reduced cofactor. Table 5 shows the results of 
control incubations for both compounds in rat hepatic tissue. The 
anaerobic metabolism of AQ4N was shown to be linear with respect to 
protein (0 to 300 Jlg per incubate) whereas the generation of AQ4 from 
AQM was linear over a protein range of 0 to 200 Jlg per incubate (Figs 17 
68 
and 18 respectively). Metabolism of both compounds was found to be 
linear over a time period of 0 to 40 min (Figs 19 and 20). 
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Fig 11. Typical Standard curves for AQ4 and AQM. Each data point 
represents the mean of three independent determinations. 
Measurements were taken using 400 Jlg of rat microsomes spiked with 
authentic AQ4 or AQM. Linear regression coefficients are displayed next 
to their appropriate curve. See materials and methods. 
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Fig 12 HPLC chromatograms for 100 IlM of A) AQ4N, B) AQM C) AQ4 
and D) a mixture of all three. 
Individual peaks are: 1) AQ4, 2) AQM and 3) AQ4N. See section 2.9 for 
HPLC conditions and detection. 
Table 5. Control incubations of AQ4N and AQM in rat hepatic tissue 
Metabolism of AQ4N Metabolism of AQM 
(nmol/incubate) (nmol/incubate) 
Conditions AQM AQ4 AQ4 
Full system + N2 5.20 + 0.90 1.75 + 0.45 7.0 + 0.80 
Full system + Air NO NO 0.50 + 0.2 
Full system - NAOPH NO NO NO 
Full system + NAOH* 0.65 + 0.20 NO 0.81 + 0.2 
Full system + CO NO NO NO 
Full system + cytosol NO NO 0.71 ± 0.2 
Full system + boiled** NO NO NO 
Full system - microsomes NO NO NO 
Results are expressed as the mean metabolite formed + SE for 60 min 
incubation. N 0= not detected. Full system were incubates containing 
200 Jlg of protein and 100 flM of either substrate (AQ4N or AQM) under 
anaerobic conditions in 0.1 M sodium/ potassium phosphate buffer (pH 
7.6), with NAOPH (4mM final concentration). Total reaction volume was 
250 JlL.*= 4mM NAOH, **= microsomes boiled for 5 min before 
incubation. 
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Fig 13. Effect of temperature on the metabolism of AQ4N. 
Results are expressed as mean metabolite formed +SE. 
for three independent incubations. Each incubate 
contained 200 J,lg of protein and 100 J,lM AQ4N. Data 
obtained at 100°C are metabolites formed after a period of 
5 minutes of boiling microsomes prior to incubation. Data 
were obtained after 60 min incubation. See section 2.7 for 
methods. 
72 
- 1 1 CI) 
• AQ4 .... as 
1 0 .c 
::J 
• AQM Cl 9 c 
.-::::: 8 • Total 0 
E 7 c 
-
c 6 
0 
5 .-.... 
as 
E 4 
... 
0 3 ,.... 
CI) 2 .... 
. -
-0 1 .c 
as 
.... 0 CI) 
:E 3 4 5 6 7 8 9 10 1 1 
pH 
Fig 14. Effect of pH on the anaerobic metabolism of AQ4N. 
Results are expressed as mean metabolite formed + SE for 
three independent incubations. Each incubate contained 
200 Jl9 of protein and 100 JlM AQM. Data were obtained after 
60 min of incubation. See section 2.7 for experimental 
conditions. 
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Fig 15. Effect of oxygen on the metabolism of 
AQ4N. 
Data were collected after 60 min incubation. 
Oxygen concentration (y axis) was measured at 
the start of an experiment (upper value) and at 
the end of the experiment (lower value) . Each 
incubate contained 200 Ilg of protein and 100 
IlM AQ4N. Values are the mean + SE for three 
determinations. See sections 2.6 and 2.7 for 
experimental conditions. NMD= No metabolites 
detected. 
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AQ4N 
Data were collected after 60 min incubation. 
Oxygen concentration (y axis) was measured at 
the start of an experiment (upper value) and at 
the end of the experiment (lower value) . Each 
incubate contained 200 J.l.g of protein and 100 
J.l.M AQM. Values are mean + SE for three 
determinations. See sections 2.6 and 2.7 for 
experimental conditions. nd= not detected. 
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Results are expressed as the mean metabolite 
formed +SE for three independent incubations. 
Incubates contained 100 JlM AQ4N and data 
were obtained after 60 min of incubation . 
See section 2.7 for experimental conditions. 
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anaerobic metabolism of AQM. 
Results are expressed as mean formation of 
AQ4 + SE for three independent incubations. 
Incubates contained 100 j.lM AQM and 
results were obtained after 60 min of incubation. 
See section 2.7 for experimental conditions. 
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anaerobic metabolism of AQ4N . 
Results are expressed as the mean of duplicate 
incubations. Each incubate contained 200 f.lg of 
protein and 100 J.lM AQ4N . Results were obtained 
after 60 min of incubation See section 2.7 for 
experimental conditions. 
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Results are expressed as mean AQ4 
formed for duplicate incubations. Each 
incubate contained 200 Jl9 of protein and 
100 JlM AQM. Data were obtained after 60 
min incubation. See section 2.7 for 
experimental conditions. 
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3.3.3 Effect of animal pretreatment on the metabol ism of 
AQ4N. 
The anaerobic production of AQ4 and AQM from A04N was increased 
(p<0.05) in microsomes from isoniazid (ISO) treated animals compared 
to untreated controls (Fig 21). Phenobarbitone (PB) pretreatment also 
caused an increase (p<0.05) in A04 generation but AQM formation did 
not significantly exceed control levels (Fig 21). The production of A04 
from AQ4N under anaerobic conditions was reduced (p<0.05) in rats 
pretreated with pregnenolone-16alpha-carbonitrile (PCN) when 
compared to tween 80 controls (Fig 21) . However, the formation of AOM 
was essentially unaffected. The generation of both metabolites by 
microsomes from 3-methylcholanthrene (3MC) pretreated animals was 
significantly reduced (p<0.01) compared to olive oil controls (Fig 21). 
Clofibrate pretreatment had no significant effect on the metabolism of 
AQ4N compared to control incubates (Fig 21). Typical chromatograms 
obtained for the anaerobic metabolism of A04N in various untreated and 
control microsomes are shown in figure 23. 
3.3.4 Effect of animal pretreatment on the metabolism of AQM 
In metabolism studies using AOM as substrate a similar trend of 
differential metabolism was obtained to that of AQ4N. ISO and PB 
induced microsomes caused an increase in AQ4 production which was 
highly significant (p<0.001) compared to control values (Fig 22) . 
Conversely 3MC and PCN induced microsomes both reduced the 
formation of AQ4 (p<0.002 and P<0.01 respectively) compared to control 
values. The production of AQ4 in CLO induced microsomes was not 
significantly different to tween 80 control values (Fig 22 ). 
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Fig 21. Effect of animal pretreatment on the 
anaerobic metabolism of AQ4N. 
Microsomes (200/.1g of protein/incubate) from 
untreated rats (UT) and rats pretreated with 
inducers of CYP were incubated with 100 /.1M of 
AQ4N for 60 min as described in section 2.7. 
Results are expressed as A) the mean ± SE for 
three determinations. Inducers are: pregnenolone-
16- alpha carbonitrile (PCN), phenobarbitone (PB), 
clofibrate (CLO), 3- methylcholanthrene (3 Me) and 
isoniazid (ISN) . Tween 80 (TWE) was the control 
vehicle for PCN and CLO. Olive oil (00) was the 
control vehicle for 3 MC. *=p<0.05, t=p<0.01 . B) 
Same date expressed as percentage of 
metabolism (levels of significance are shown in A) 
only) . 
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Fig 22. The effect of animal pretreatment on the 
anaerobic metabolism of AQM. 
Microsomes (200 ~g of protein/incubate) from 
untreated rats (UT) and rats treated with CYP 
inducers were incubated with 100 11M of AQM for 
60 min as described in section 2.7. Results are 
expressed as A) the mean ± SE for three 
determinations. Inducers are: pregnenolone- 16-
alpha carbonitrile (PCN), clofibrate (CLO) , 3-
methylcholanthrene (3MC) and isoniazid (ISN). 
Tween 80 (TWE) was the control vehicle for PCN 
and CLO. Olive oil (00) was the control veh icle 
for 3MC. t=p<0.01, tt=p<0.001 and t*=p<0.002 
B) is the same data expressed as percentage of 
metabolism (levels of significance are shown in 
A) only. 
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Fig 23. Typical HPLC chromatograms obtained after incubating 100 
J.l.M AQ4N in NADPH supplemented rat microsomes for 60 min 
Incubations were carried out under anaerobic conditions as 
described in section 2.7. Chromatograms are from A) untreated (UT) 
animals, B) Isoniazid (ISO) induced animals, C) 3-
methylcholanthrene (3 Me) induced animals and D) UT animals after 
carbon monoxide purge. Peaks are: 1) AQ4, 2) AQM and 3) AQ4N 
3.3.5 Effect of inhibitors on the metabolism of AQ4N in rat 
microsomes 
Ketoconazole (100 J.lM) completely inhibited the formation of AQ4 by 
untreated rat microsomes and the formation of AQM was reduced to 15 
% of control levels. 30 J,lM diethyldithiocarbamate (DIE) completely 
inhibited AQ4 formation in ISO induced microsomes and reduced AQM 
production to 57 % of control values. Metyrapone (MET) inhibition of PB 
induced microsomes was concentration dependent, having essentially 
no effect at 1 J.lM, but reducing AQ4 and AQM production to 21 and 590/0 
respectively of control values at 10 J,lM (Fig 24). Carbon monoxide and 
air completely abolished the metabolism of AQ4N in untreated rat 
microsomes (Table 5). 
3.3.6 Effect of inhibitors on the metabolism of AQM in rat 
microsomes 
KET (100 J.lM) reduced the formation of AQ4 to 10% of control values in 
untreated microsomes. ISN induced microsomes produced 32% of AQ4 
compared to control values in microsomes preincubated with 30 J,lM DIE. 
MET was effective at 10 J.lM in inhibiting the formation of AQ4 to 20% of 
control values in PB induced microsomes (Fig 25). Carbon monoxide 
inhibited completely the anaerobic metabolism of AQM and air saturated 
incubates caused a reduction in AQ4 generation to 6.4% of anaerobic 
incubations (Table 5 ). 
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Fig 24. Effect of CYP inhibitors on the anaerobic 
metabolism of AQ4N in rat hepatic microsomes. 
Results are expressed as percentage metabolite 
formation + % SE for three determinations relative to 
control incubations carried out in the absence of 
inhibitor. Each incubation contained 200 Jlg of 
protein and 100 JlM AQ4N. Animal pretreatments 
were: untreated (UT), isoniazid (ISN) and 
phenobarbitone (PB). Inhibitors were: ketoconazole 
(KET), diethyldithiocarbamate (DIE), metryrapone 
(MET) and carbon monoxide (CO). See section 2.7.1 
for experimental conditions. 
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Fig 25. Effect of CYP inhibitors on the anaerobic 
metabolism of AQM in rat hepatic microsomes. 
Results are expressed as percentage metabolite 
formation for replicate determinations relative to 
control incubations carried out in the absence of 
inhibitor. Each incubation contained 200 Jlg of 
protein and 100 J.lM AQ4N. Animal pretreatments 
were: untreated (UT), isoniazid (ISO) and 
phenobarbitone (PB). Inhibitors were: ketoconazole 
(KET), diethyldithiocarbamate (DIE), metyrapone 
(MET) and carbon monoxide (CO). See section 
2.7.1 for experimental conditions. 
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3.3.7 Oxidative metabolism of AQ4 in rat hepatic tissue 
The investigation into the oxidative metabolism of AQ4 produced results 
which are shown in figure 26. Only 80/0 of AQ4 was oxidised to a 
metabolite with identical spectral and chromatographic properties to 
AQM. The process was 640/0 inhibited in incubates containing 1 00 ~M 
KET and completely inhibited in incubates gassed with carbon 
monoxide. Furthermore, anaerobic conditions abolished AQ4 oxidation. 
Metabolism was not detected in incubates depleted of NADPH or 
microsomes. Incubates containing heat denatured microsomes (boiled 
for 5 minutes before use) failed to support metabolism. 
3.3.8 Kinetics of AQ4N and AQM metabolism in untreated rat 
microsomes 
The untransformed kinetic data for initial reaction velocity versus 
substrate concentration were subjected to observer independent non 
linear curve fitting analysis as described in section 2.7.3. Using this 
method, the anaerobic metabolism of AQ4N to both AQ4, AQM and total 
substrate turnover was found to conform to Michaelis-Menten kinetics 
(Fig 27). A Hanes-Woolf transform of the kinetic data produced a plot 
which was linear with respect to both metabolites and total substrate 
turnover (Fig 28 ) and allowed kinetic parameters to be established. 
However, when AQM was used as substrate, plots of initial reaction 
velocity versus substrate concentration fitted perfectly to sigmoid kinetics 
as described by the Hill equation (Fig 29). Furthermore, a Hanes- Woolf 
transform generated a non linear plot (Fig 30) which is consistent with 
deviation from Michaelis- Menten behaviour. The kinetic parameters for 
both substrates are shown in table 6. 
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Fig 26. Oxidative metabolism of AQ4 in untreated rat 
hepatic microsomes. 
Data are expressed as in A) as the mean of two 
determinations. Incubates contained 200 Jlg of protein and 
100 JlM AQ4. Data were collected after 60 min of aerobic 
incubation. UT = untreated, DMSO= UT + dimethyl 
sulphoxide and KET = UT + ketoconazole (1 OOJlM). 
B) same data expressed as a percentage of metabolism. 
See section 2.7.2 for experimental conditions. 
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Fig 27. Effect of AQ4N concentration on the initial 
velocity of anaerobic metabolism. 
Incubates contained 200 Jlg of protein and data are 
expressed as the mean of three determinations, 
taken after 40 min incubation. AQ4 formation (black 
squares), AQM formation (open triangles) and total 
metabolism (black triangles). Solid lines are curves 
of best fit. See section 2.7 for experimental conditions _ 
and section 2.7.3 for kinetic analysis. 
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kinetic data from figure 27 . 
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Table 6 Kinetic parameters for AQ4N and AQM metabolism m rat 
microsomes 
Substrate 
AQ4N 
AQM 
Metabolite Km·(JlM) V max 
AQM 
AQ4 
Total 
AQ4 
38.76 
5.65 
30.29 
27.00 
0.92 
0.13 
1.05 
1.72 
n* 
NA 
NA 
NA 
3 
23.7 
23.0 
34.0 
63.0 
~es.ult~ are means of three determinations. *n= Hill coefficient, CLint 
(mtrlnslc clearance) = VmaxlKm and NA= not applicable. Units for Vmax= 
nmol metabolite formed/mg of protein/min. Units for CLint= JlUmg/min. Total= sum of metabolites (AQM+AQ4). 
3.3.9 SOS- Page characteristics and activities of Purified 
CPR, HO- 1 and nNOS. 
The cytochrome P450 reductase enzyme (CPR) ran to a position 
corresponding to approximately 80 KD on a 12.5% polyacrylamide SDS 
gel (Fig 31). This was in good agreement with the published molecular 
mass of the enzyme (Workman and Walton 1990). However, two other 
minor bands of unknown identity were also detected at positions 
corresponding to approximately 66 KD (see figure 31). Despite these 
minor impurities the preparation was highly active (2.0 Jlmollmglmin) in 
the reduction of oxidised cytochrome c. The truncated HO-1 protein was 
found to be a highly purified preparation as only a single band was 
detected by SDS- PAGE at a molecular weight corresponding to the 
published molecular weight of the enzyme (Wilks and Ortiz de 
Montellano 1993). The enzyme had an activity of 93 nmoll mg/min 
(mean of two determinations). The activity of nNOS was found to be 0.21 
f..Lmollmglmin (mean of two determinations). 
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Fig 31. SDS- PAGE for A) purified HO- 1 and 8) partially purified CPR. 
Gels were run as described in section. In A) 3Jlg of HO- 1 were loaded 
in lane 1. Molecular mass standards are in lane 2 and are : albumin 
(66KD), ovalbumin (45 KD), glyceraldehyde 3- phosphate 
dehydrogenase (36 KD), carbonic anhydrase (29 KO) and trypsinogen 
(24 KD),. In 8) 3 Jlg of CPR were loaded in lane 1 and the same 
molecular mass standards as used in A) are in lane 2. 
3.4. Metabolism of AQ4N in experiments uSing recombinant 
nNOS and the CPR/ HO- 1 system 
The results of anaerobic metabolism experiments using nNOS and the 
CPR/ HO- 1 system are shown in table 7. With respect to incubat ions 
containing nNOS , 120 min anaerobic incubation resulted in the 
generation of both A04 and AOM . Aerobic incubations produced both 
metabolites however, A04 and AOM production was 2.3 and 2.7 fol d 
lower respectively than anaerobic incubations . Metabol ism was not 
detected in incubates without NAOPH or nNOS. Although anaerobic 
metabolism of AQ4N was detected in incubates containing the CPR! HO-
·1 system, the presence of HO-1 caused a small, albeit, significant 
(P<0.05) reduction in the amount of AQ4 formed. A peak corresponding 
to AQM was not detected in incubates containing the CPR! HO-1 system 
(with or without HO-1) and metabolism was not detected in aerobic 
incubates containing the system with or without HO-1. Similarly, 
metabolites were not detected in incubates minus HO-1 when either 
NAOPH, haemin or when CPR were removed. 
Table 7. Anaerobic metabolism of AQ4N by purified nNOS and the 
CPR! HO-1 enzyme system 
Conditions 
nNOS+ NAOPH+AQ4N 
minus air 
CPR+ HO- 1 + haemin+AQ4N 
+NAOPH minus air 
CPR+ haemin+ AQ4N+NAOPH 
minus air 
AQ4 AQM 
0.52 ± 0.03 5.9 + 0.04 
2.55 + 0.33 NO 
3.18 ± 0.11* NO 
Results are expressed as nmol of metabolite for:nedlincubate after 120 
min of anaerobic incubation. Each result IS the mean of three 
independent determinations + SE. See sections 2.8.2 and. 2.8.4 for 
experimental conditions. * significantly different (P< 0.05) from Incubates 
containing HO-1. HO-1 =haem oxygenase, CPR= cytochrome P450 
reductase and NO= not detected. 
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3.5. Conclusions 
1) In rat hepatic microsomes, the novel anthraquinone di-N-oxide 
prodrug, AQ4N was metabolised under physiological conditions by a 
process that shows a marked preference for NADPH over NADH as 
reduced cofactor and was inhibited by air. Furthermore, the anaerobic 
metabolism of this prodrug did not occur in the cytOsol and was inhibited 
by the general CYP inhibitors ketoconazole (100 J!M) and carbon 
monoxide. In addition, AQ4 was oxidised to AQM under aerobic 
conditions in a process inhibited by ketoconazole. 
·2) Rat hepatic microsomes also mediated the anaerobic metabolism of 
AQM (the two electron reduced mono-N-oxide of AQ4N) to AQ4. The 
metabolism, like that of AQ4N, was inhibited by air, carbon monoxide 
and ketoconazole. The metabolism occured maximally when NADPH 
was used as reduced co factor and cytosolic metabolism was found to be 
approximately 10% of that observed in microsomes (see Table 5). 
3) Microsomes from rats pre treated with known GYP inducers 
anaerobically metabolised AQ4N to different extents. Interestingly, when 
AQM was used as substrate, a similar profile of differential metabolism 
was obtained to that of AQ4N. Specifically ISO (GYP 2E inducer) and 
PB (CYP 2B inducer) pretreatment significantly enhanced the 
metabolism of both compounds. Whereas 3 MG and PCN pretreatments 
produced microsomes which repressed the metabolism of both AQ4N 
and, in separate experiments, the mono-N-oxide (AQM) compared to 
uninduced microsomes. Furthermore, inhibition studies confirmed that 
CYP 2E and CYP 2B were the major rat CYPs involved in the 
metabolism of AQ4N and AQM. 
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4) The kinetics of AQ4N metabolism conformed to a classic Michaelis-
Menten model. This was true for the generation of AQM, AQ4 and total 
substrate turnover (sum of metabolites). In contrast, the kinetics of AQM 
metabolism were found to be better described by sigmoid kinetics. 
The kinetic parameters Vmax , Km and CLint were determined for the 
metabolism of both compounds and demonstrated that AQM was a better 
substrate (higher V max, and higher CLint) for rat hepatic microsomes than 
AQ4N. 
5) Preliminary experiments demonstrated that AQ4N was a substrate for 
purified rat nitric oxide synthase (nNOS) and partially purified 
cytochrome P450 reductase (CPR). The latter enzyme requiring haem 
for activity. However, the anaerobic metabolism of AQ4N by CPR with 
haem was decreased in the presence of human haem oxygenase. 
In summary, both AQ4N and the mono-N-oxide AQM undergo hypoxia 
dependent metabolism in the presence of rat hepatic microsomes and 
NADPH. In addition, AQ4 underwent a small amount of oxidation under 
aerobic conditions and in the presence of NADPH. Differential 
metabolism studies and the use of inhibitors demonstated that rat 
hepatic CYPs metabolised both of these compounds. Furthermore, both 
compounds were substrates for rat hepatic CYP 2E and 2B. In addition, 
preliminary experiments suggested that CPR (in combination with haem) 
and nNOS were both able to metabolise AQ4N. 
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Chapter 4 
Metabolism of AQ4N and AQM in human subcellular fractions 
4.1 Aims 
To investigate the role of the human CYP enzymes in the metabolism of 
AQ4N and AQM in a variety of human subcellular fractions and in some 
clinically resected human renal and colonic tumours. 
4.2 Materials and Methods 
The approach adopted to identify human CYP enzymes responsible for 
the metabolism of both the prodrug AQ4N and the mono-N-oxide AQM 
have been outlined in detail in section 2.1. Livers of road accident victims 
or those taken from organ donor patients were kindly provided by 
Professor M Danny Burke, clinicopathological data for each liver are 
shown in table 2. Clinically resected human tumours along with the 
corresponding samples of heathy tissue were provided by Dr G I Murray 
and the details for each tumour are shown in table 3. Gene transfected 
human Iymphoblastoid cell microsomes were obtained from the source 
cited in section 2.2.2. 
4.2.1 Protein determination 
All tissue protein was quantified by the method described in section 2.5. 
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4.2.2 Metabolism of both AQ4N and AQM in human subcellular 
fractions 
Anaerobic conditions were obtained in an identical manner to that 
described in the previous chapter and are detailed in section 2.6. 
Metabolism of AQ4N and, where possible AQM, in human liver, renal, 
colon and various human tumours was carried out by the method 
described in section 2.7. CYP specific inhibtors were also used in 
separate metabolism studies using the method described in section 2.7.1. 
Oxidative metabolism of AQ4 was determined in two individual livers by 
the method described in section 2.7.2. 
4.2.3 Correlation analysis 
Distribution free Spearman Rank correlation between the anaerobic 
metabolism of both AQ4N and AQM and various CYP activities in human 
liver microsomes was determined by the method described in section 
2.9.1. 
4.2.4 Kinetic analysis 
The kinetics of AQ4N bioreduction were analysed in an identical manner 
to that used for the rat mediated metabolism. The observer independent 
software used allowed for a simultaneous fitting of data to classic kinetic 
equations and is described in section 2.7.3. 
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4.2.5 Metabolism of AQ4N in human gene transfected cell 
microsomes 
The CYP 3A and CPR activities of human Iymphoblastoid cell 
microsomes were assayed as described in section 2.8.3. The 
metabolism of AQ4N by Iymphoblastoid cell microsomes transfected with 
separate cDNA sequences for CYP 3A4, CYP 286 and CPR is described 
in section 2.8.5. 
4.2.6 HPLC and Metabolite detection 
At appropriate times, all metabolic incubations were terminated and 
deproteinised (section 2.9). The metabolites of either AQ4N or AQM 
were analysed and quantified by reverse phase isocratic HPLC as 
described in detail in section 2.9. 
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4.3 Results 
4.3.1 Metabolism of AQ4N and AQM in human hepatic tissue 
Anaerobic metabolism of AQ4N (100 J.1M) was supported in all human 
liver microsomes (HLM) tested. In incubates containing 400 J.1g of protein, 
the range (+ SE) of total metabolism after 60 min incubation was 14.26 ± 
1.43 (highest) to 3.65 + 1.05 nmoVincubate (lowest) (Fig 32 and 33). In 
separate experiments where 100 J.1M AQM was used as substrate and 
incubations contained 100 J.1g of protein, the range of AQ4 formation (+ 
SE) after 60 min incubation was 4.24 + 0.3 (highest) to 1.42 + 0.2 (lowest) 
(Fig 34). Metabolism of both compounds was undetectable in incubates 
purged with carbon monoxide, depleted of NADPH or in incubates 
containing heat denatured (boiled for 5 min) microsomes. In air saturated 
incubates, the metabolism of AQ4N to AQM was routinely less than 4% of 
anaerobic controls whereas the production of AQ4 was not detected. 
Metabolism of AQ4N to both metabolites was undetected in cytosolic 
fractions. When AQM was used as substrate, the anaerobic generation 
of AQ4 in cytosol was consistently less than 100/0 of the value obtained in 
microsomes. 
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Fig 32. Anaerobic metabolism of 1 OO~M AQ4N 
in a panel of 17 human liver microsomes (HLM's). 
Incubations contained 400 Jlg of protein and data 
were obtained after 60 min incubation. Results are 
expressed as the mean ± SE for three independent 
determinations. See section 2.7 for experimental 
methods. 
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AQ4N in a panel of 17 human liver microsomes. 
Data are derived from figure 32 and are expressed as 
the mean percentage metabolism ± % SE 
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Incubates contained 100 J.1g of protein and 100 J.1M 
AQM. Data were taken after 60 min incubation and are 
expressed as A) the mean ± SE for three independent 
determinations or B) percentage metabolism. See 
section 2.7 for experimental conditions. 
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4.3.2 Correlations between the metabolism of AQ4N and AQM and 
markers of CYP activity/content 
Scattergrams and Spearman rank correlation coefficients (rs) for the 
metabolism of both AQ4N and AQM versus various GYP activities/isoform 
content are shown from Figure 35 through to Figure 37. Significant 
correlations (p <0.01) were obtained for the metabolism of AQ4N and two 
CYP 3A markers, namely benzoxylresorufin O-deethylation (BROD) and 
tamoxifen N-demethylation (TND). AQ4N metabolism was not 
significantly correlated with markers of GYP 2G, 1A, 2A or 20 (Table 8). 
Similarly, the metabolism of AQM correlated strongly (p<0.01) with BROD 
activity (rs= 0.74, N=14) and to a lesser extent (p<0.05) with tamoxifen N-
demethylation (rs= 0.83). Interestingly, AQM metabolism also correlated 
with coumarin 7-hydroxylase activity (p<0.05), a marker of GYP 2A 
activity (Fig 37 C). The metabolism of AQM to AQ4 correlated strongly 
with the overall four electron reduction of AQ4N to AQ4 (p<0.01) (Fig 38 
A). However, the metabolism of AQM to AQ4 correlated only weakly 
(p<0.05) with the two electron reduction of AQ4N to AQM and the total 
metabolism of AQ4N (Fig 38 Band G respectively). Like AQ4N, AQM 
metabolism did not correlate with markers of GYP 1A12G or 20 (Table 9). 
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Fig 35. Correlations between Benzyloxyresorufin 0-
deethylase (BROD) activity and the anaerobic metabolism 
of AQ4N 
Data from figure 30 were subjected to Spearman rank 
correlation analysis, (N= 17). Regression lines are shown 
for correlations that reach significance at p<0.01 A) AQ4 
formation. B) AQM formation and C) total metabolism. 
See section 2.7 for experimental conditions and 2.9.1 for 
analysis. 
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Fig 36. Correlations between tamoxifen N-
demethylation (TND) and the anaerobic metabolism 
of AQ4N. 
Data from figure 30 were subjected to Spearman 
rank correlation analysis, (N=17). Regression lines 
are shown for correlations that reach significance at 
p<0.01. A} AQ4 formation, 8) AQM formation and 
C) total metabolism. See section 2.7 for 
experimental methods and 2.9.1 for analysis. 
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Table 8. No~ significant Spearman rank correlations (p>O.OS) 
between vanous CYP activities/ isoform content and the anaerobic 
metabolism of AQ4N in human liver microsomes. 
Metabolite 
AQ4 
AQM 
Total 
AQ4 
AQM 
Total 
AQ4 
AQM 
Total 
AQ4 
AQM 
Total 
AQ4 
AQM 
Total 
CYP activity/ content 
tolbutamide hydroxylation 
tolbutamide hydroxylation 
tolbutamide hydroxylation 
CYP 2C content 
CYP 2C content 
CYP 2C content 
coumarin hydroxylation 
coumarin hydroxylation 
coumarin hydroxylation 
CYP 1 A content 
CYP 1 A content 
CYP 1 A content 
DMOD 
DMOD 
DMOD 
CYP marker 
CYP2C 
CYP2C 
CYP2C 
CYP2C 
CYP2C 
CYP2C 
CYP2A 
CYP2A 
CYP2A 
CYP1A 
CYP1A 
CYP1A 
CYP2D 
CYP2D 
CYP2D 
rs p value N 
0.05 0.84 17 
0.13 0.59 17 
0.15 0.65 17 
0.37 0.12 17 
0.23 0.36 17 
0.31 0.20 17 
0.31 0.31 12 
0.08 0.80 12 
0.19 0.53 12 
-0.13 0.68 12 
-0.02 0.94 12 
-0.04 0.89 12 
-0.08 0.80 12 
0.04 0.90 12 
0.07 0.82 12 
Correlations were based on the data shown in figure 32. Total= sum of 
metabolites, DMOD= dextromethorphan O-demethylation, . 
rs= Spearman rank correlation coefficient and N= number of livers 
tested. CYP 2C and 1A contents were measured by western blotting 
using polyclonal antibodies (section 2.9.1). 
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Fig 37. Correlations between the anaerobic metabolism 
of AQM to AQ4 and various CYP activities. 
Data from figure 34 were subjected to Spearman rank analysis. 
Regression lines are shown for correlations that reached 
significance at p<O.05 and p<O.01. A) benzyloxyresorufin 0-
deethylase (BROD) activity (N= 14), 8) tamoxifen N- demethylase 
(TND) activity (N= 9), and C) coumarin 7- hydroxylase (CHA) 
activity (N= 9). See section 2.7 for experimental conditions and 
2.9.1 for analysis. 
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Fig 38. Correlations between the anaerobic 
metabolism of AQM and the anaerobic metabolism of 
AQ4N. 
Data from figures 32 and 34 were subjected to 
Spearman rank correlation analysis (N= 14). 
Regression lines are shown for correlations that 
reached significance at p<O.05. A) AQ4 from AQ4N. 
B) AQM from AQ4N and C) total metabolism of AQ4N. 
See section 2.7 for experimental conditions and 2.9.1 
for analysis. 
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Table 9. No~ significant Spearman rank correlations (p>0.05) 
betwee~ vanous Cy~ activities/ isoform content and the anaerobic 
metabolism of AQM In human liver microsomes. 
CYP activity! content CYP marker rs p value N 
tolbutamide hydroxylation CYP 2C 0.00 1.00 14 
CYP 2C content CYP2C 0.43 0.12 14 
CYP 1A content CYP1A -0.28 0.38 11 
DMOD CYP2D 0.42 0.23 9 
Correlations were based on the anaerobic production of AQ4 as 
shown in figure 34. DMOD= dextromethorphan O-demethylation, 
rs= Spearman rank correlation coefficient and N= number of livers 
tested. CYP 2C and 1 A contents were measured by western blotting 
using polyclonal antibodies (section 2.9.1). 
4.3.3 Effect of inhibitors on the metabolism of AQ4N in human liver 
microsomes 
The effect of inhibitors was investigated in three individual liver 
microsome preparations, HLM 50, HLM 45 and HLM 55. Alpha 
naphthoflavone (ANF;1 0 f.1M) had essentially no effect on the metabolism 
of AQ4N in all livers tested. Triacetyloleandomycin (TAO;50 J.lM) inhibited 
completely the formation of AQ4 in all three HLM preparations. AQM 
production was inhibited by 71 % in HLM 50, 82% in HLM 45 and 100% in 
HLM 55. KET (100 f.1M) and carbon monoxide prevented the formation of 
any detectable metabolites in all three HLM preparations tested (Fig 39 to 
41). Typical chromatograms for control and TAO inhibition of AQ4N 
metabolism are shown for HLM 55 (Fig 42). 
112 
125 
0 AQ4 100 ":. c 
0 ~ AQM ... 
as 
E-
... 0 75 o ... 
....... 
c 
(I) 0 
::u 
50 -o 0 
.c'" 
as (I) 
a; > E+= as 25 
-
'i!!.(I) o ... 
0 n.m.d 
LL 0 0 Z <t .... 0 <t .... w ~ 
:= := ~ :::i. :::i. 
:::i. 
0 0 c ~ It) c 
,.... 
Fig 39. Effect of CYP inhibitors on the anaerobic 
metabolism of AQ4N in microsomes from HLM 50. 
Results are expressed as mean percentage metabolite 
formation + % SE for three determinations relative to 
control incubations carried out without CYP inhibitor. 
Each incubate contained 400 /-lg of protein and 100 
JlM AQ4N. Data were obtained after 60 min incubation 
and inhibitors are: alpha- naphthoflavone (ANF), 
triacetyloleandomycin (TAO), ketoconazole (KET) and 
carbon monoxide (CO). See section 2.7.1 for 
experimental conditions. n.d=not detected, n.m.d=no 
metabolites detected. 
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Fig 40. Effect of CYP inhibitors on the anaerobic 
metabolism of AQ4N in microsomes from HLM 45. 
Results are expressed as mean percentage 
metabolite formation + % SE for three 
determinations relative to control incubations carried 
out without CYP inhibitor. Each incubate contained 
400 Jl9 of protein and 100 JlM AQ4N. Data were 
obtained after 60 min incubation and inhibitors are: 
alpha naphthoflavone (ANF), triacetyloleandomycin 
(TAO), ketoconazole (KET) and carbon monoxide 
(CO). See section 2.7.1 for experimental conditions. 
n.d=not detected and n.m.d=no metabolites 
detected. 
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Fig 41. Effect of CYP inhibitors on the anaerobic 
metabolism of AQ4N in microsomes from HLM 55. 
Results are expressed as mean percentage metabolite 
formation + % SE for three determinations relative to 
control incubations carried out without CYP inhibitor. 
Each incubate contained 400 Ilg of protein and 100 JlM 
AQ4N. Data were obtained after 60 min incubation and 
inhibitors were: alpha naphthoflavone (ANF), 
triacetyloleandomycin (TAO), ketoconazole (KET) and 
carbon monoxide (CO). See section 2.7.1 for 
experimental conditions. n.md=no metabolites 
detected. 
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Fig 42. Typical HPLC chromatograms for the 
anaerobic metabolism of 100 11M AQ4N in HLM 55. 
Chromatograms have been taken after 60 min . 
incubation in experiments using 400 J.L9 of protein 
and are A) incubation in DMSO and B) incubation 
using 50 J.LM troleandomycin (TAO). Peaks are 
1) AQ4, 2) AQM and 3) AQ4N. 
4.3.4 Kinetics of AQ4N metabolism in human liver microsomes 
Initial reaction velocities for the anaerobic metabolism of AQ4N in three 
separate human liver microsome preparations were found to be linear 
with respect to time from 0 to 40 min (Figs 43 to 45). A slight lag in 
reaction velocity was observed for HLM 50 and 45 at protein 
concentrations up to 160 Ilg before becoming linear up to approximately 
400 Ilg (Figs 46 and 47 respectively). HLM 55 kinetics were linear with 
respect to protein from 0 to 400 J.!g (Fig 48). Untransformed kinetic data 
for the effect of substrate concentration versus initial reaction velocity, for 
. all three individual livers, were subjected to observer independent non 
linear curve fitting analysis (section 2.7.3 ) and subsequently shown to 
conform to Michaelis-Menten kinetics (Figs 49 to 51). Hanes-Woolf 
transforms of the kinetic data generated linear plots (Figs 52 to 54 ) from 
which the kinetic parameters were derived (Table 10 ). 
4.3.5 Oxidative metabolism of AQ4 in human liver microsomes 
Oxidative metabolism of AQ4 was investigated in two human liver 
microsome preparations, HLM 47 and HLM 55. In both preparations 60 
min incubation, using 400 Ilg of protein, resulted in a single peak with 
identical chromatographic and spectral properties to AQM (range: (HLM 
55) 0.77 nmol- (HLM 47) 0.66 nmol). No metabolism was detected in 
incubates minus NADPH or microsomes or in incubates containing heat 
denatured microsomes or the CYP inhibitors KET (1 OOJ.!~ or CO. (Figs 
55 and 56). Furthermore, no N-oxidation occurred under hypoxia 
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Fig 52. Hanes- Woolf transform of the kinetic 
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Table 10. Kinetic data for the anaerobic metabolism of AQ4N in three 
human livers 
Liver 
HLM50 
HLM45 
HLM 55 
Metabolite 
AQM 
AQ4 
total 
AQM 
AQ4 
total 
AQM 
AQ4 
total 
Km Vmax 
(JlM) (nmol/mg/min) 
70 0.25 
25 0.02 
50 0.27 
30 0.31 
22 0.04 
45 0.35 
48 0.34 
16 0.05 
40 0.40 
3.5 
0.8 
5.2 
10 
1.8 
7.7 
7.0 
3.2 
10 
Results are expressed as the mean of three determinations. CLint 
(intrinsic clearance)= Vmax/Km. Units for CLint are JlUmg/min. Total= 
sum of metabolites (AQM +AQ4). 
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4.3.6 Metabolism of AQ4N in human Iymphoblastoid cell 
microsomes 
Human Iymphoblastoid cell microsomes containing vector transfected 
CYP 3A4 protein were found to have a BROD activity of 0.013 
nmol/mg/min (mean of two determinations). Activity was undetectable in 
incubates using the CYP 3A inhibitor TAO (50 JlM). Microsomes from 
CPR vector transfected cells were found to have a cytochrome c 
reductase activity of 3.5 Jlmol/mg/min (mean of two determinations). 
Control microsomes (without inserts for CYP 3A4 or CPR) had no 
detectable activity for either BROD or the reduction of cytochrome c. 
Microsomes from CYP 3A4 transfectants supported the anaerobic 
metabolism of AQ4N to both AQM and AQ4 (Fig 57). Metabolism was 
not apparent in CYP 3A4 transfected microsomes incubated with 50 J.lM 
TAO, in air saturated incubates, or in incubates depleted of NADPH. 
Similarly, microsomes transfected with CPR or CYP 2B6 were unable to 
metabolise AQ4N (Fig 57). Metabolism of AQ4N to AQM in control 
microsomes was 3.50/0 of CYP 3A4 values whereas AQ4 production was 
not detected. 
4.3.7 Metabolism of AQ4N in human tumour and paired healthy 
tissue 
Metabolism of AQ4N was supported in both normal and neoplastic kidney 
(Fig 58). In renal cell carcinoma microsomes (HKT5) the anaerobic 
dependent production of both metabolites was approximately 3 fold less 
than the corresponding healthy kidney (HK5). However, in a second 
individual the production of AQ4 in renal cell carcinoma microsomes 
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(HKTS) was only 1.5 fold less than the paired healthy tissue (HK6). The 
same individual produced 13 fold less AQM in carcinoma microsomes 
compared to healthy kidney (Fig 58). AQM was also detected in all 
colonic tissue (Fig 59). For example the ratio of AQM production in 
normal versus neoplastic colon was approximately 2.5/1 for both 
individuals. AQ4 was detected in the healthy colon of one individual only 
(HC5; Fig 59). Production of AQM was routinely < 5% in normal and 
neoplastic tissue of kidney and colon in air, NADPH depleted or in 
incubates containing heat denatured microsomes. Whereas under these 
conditions, AQ4 was not detected. Furthermore, carbon monoxide purge 
prevented the formation of either metabolite in normal and neoplastic 
tissue of both the kidney and colon. 
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4.4 Conclusions 
1) The reductive metabolism of both AQ4N and AQM, were shown to 
occur under anaerobic conditions by a process that was inhibited by air 
and requires NADPH as reduced co factor. Furthermore, the metabolism 
of both compounds was limited to the microsomal fraction and was 
inhibited by the general GYP inhibitor CO. AQ4 was oxidised to AQM 
under aerobic conditions in the presence of microsomes and NADPH. 
However, compared to reductive metabolism the amount of oxidation was 
very small. 
2) The anaerobic metabolism of both compounds was found to correlate 
strongly with GYP 3A activity but not with the activities of CYPs 1 A, 2C or 
2D. Interestingly, the anaerobic metabolism of AQM was also found to 
correlate with GYP 2A activity. The involvement of CYP 3A in the 
anaerobic metabolism of AQ4N was confirmed, in three individual livers, 
by the inhibition of metabolism in experiments using the CYP 3A specific 
inhibitor TAO. No inhibition occurred in anaerobic incubates containing 
the GYP 1 Al2G inhibitor ANF. This finding was consistent with the 
correlation data and confirmed that GYPs 1 A and 2C were not involved in 
AQ4N bioreduction. 
4) Experiments using gene transfected human microsomes demonstrated 
that GYP 3A4 was capable of AQ4N bioreduction. GYP 286 and CPR 
transfectants were unable to support metabolism. 
S) The kinetics of AQ4N metabolism were investigated in three individual 
livers and were shown to conform to a Michaelis-Menten type model. 
Although some variation was found between the intra-individual Km values 
with respect to the two electron reduction of AQ4N to AQM, the Km values 
for the production of AQ4 and total metabolism were similar for each 
individual and were consistent with the same enzyme in all three 
individuals metabolising AQ4N. Vmax values were found to be 
commensurate with the extent of metabolism so that HLM SO (lowest Vmax 
value) could be described as a poor metaboliser, whereas HLM 55 
(highest V max) could be described as a good metaboliser. This trend was 
also apparent in the calculated GLint values which decreased in the order 
HLM SS>HLM 4S>HLM SO. 
6) AQ4N has been shown to be a substrate for human normal and 
neoplastic kidney and normal and neoplastic colon. The metabolism 
occurred in both tissue types and was dependent on anaerobic conditions 
and the presence of NADPH. Furthermore, it appears that CYP enzymes 
were involved in the tumour mediated metabolism of AQ4N as metabolites 
were absent in incubates anaerobically purged with the CYP inhibitor CO. 
In conclusion, human microsomes supported the anaerobic metabolism of 
both AQ4N and AQM. The process was inhibited by air and was 
predominantly catalysed by CYP 3A enzymes. CYP 3A4 has been shown 
to be at least one member of the GYP 3A family capable of metabolising 
AQ4N. However, the present findings do not exclude the possibility that 
GYPs 3AS, 3A3 and 3A? can anaerobically activate AQ4N. Human 
tumours were able to support the anaerobic metabolism of AQ4N and this 
process was probably mediated by CYP enzymes. 
Chapter 5 
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Chapter five 
Preliminary investigation into the in vivo metabolism of AQ4N in 
tumour and non tumour bearing mice. 
5.1 Aims 
In 1995 Cole and coworkers discovered that administration of AQ4N (250 
mg/kg of body weight) in combination with a single dose of 25 Gy to mice 
bearing a variety of tumours produced some interesting pharmacodynamic 
results. In particular RIF- 1 and SCCV11 neoplasms were found to be 
sensitive to the treatment whereas KHT tumours were essentially 
unaffected. The aims of this preliminary investigation were to 1) Identify 
AQ4N metabolites in both rodent and human tumours xenografts, namely 
RIF-1, SCCVII and KHT (rodent) and HT29 (human), freshly excised from 
mice and so confirm that prod rug metabolism is not restricted to the in vitro 
setting and 2) Establish whether the quantity of cytotoxiC AQ4 detected in 
RIF- 1, SCCV11, and KHT tumours correlated with their in vivo sensitivity as 
determined by Cole et al (1995). A third aim was to determine the extent of 
AQ4N metabolism in non tumour tissue including plasma, liver, gall bladder 
and hind leg muscle. 
5.2 Materials and Methods 
C3H female and male nude mice were obtained from Charles River Ltd 
(Margate, UK). All standard laboratory reagents were obtained from the 
sources detailed in section 2.2. 
5.2.1 Animal dosing procedure* 
Animals were dosed by the procedure described in section 2.9.3. 
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5.2.3 Drug and metabolite extraction 
Drug and metabolite extraction were performed as described in section 
2.9.4. 
5.2.4 Protein analysis 
All tissue protein was quantified as described in section 2.5. 
* All animal work including the growth of tumours, administration of AQ4N and the resection of 
tissue for analysis was carried out by members of the technical staff at the MRC Radiobiology 
Unit, Chilton, Didcot, Oxon, UK. 
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5.3 Results 
5.3.1 Drug and metabolite recovery 
The recovery of standards made up in the presence of tissue homogenates 
was compared to standards made up in the absence of tissue. Typical 
recoveries over six concentrations were: AQ4N (24.60/0), AQM (29.00/0) and 
AQ4 (25.80/0). 
5.3.2 Tumours 
In general, AQ4 was the principle metabolite detected in all tumour samples 
(Table 11 to 14), and was highest in the HT29 tumour (45.86 pmol/mg) 1 
hour after dosing. At the same time point, AQM and AQ4N were 6.8 and 
15.5 fold lower respectively. At 48 hours the amount of AQ4 had decreased 
to 5% of the amount detected at 1 hour and AQM and AQ4N were 
undetectable at 48 hours. In KHT tumours, AQ4 and AQM were detected 15 
minutes after dosing, although by1 hour the amount of AQ4 had increased 
approximately 2.5 fold and was undetectable thereafter. AQM was 
detectable 15 minutes after dosing but was not detected from 1 hour to 48 
hours. AQ4N was not detected in KHT tumours at any time point tested. In 
RIF tumours, AQ4 was present at 24 and 48 hours after dosing, AQM was 
only detected after 15 minutes and AQ4N, like in KHT tumours, was absent 
at all time points. In SCCVII tumours, AQ4 was detected after 15 minutes 
(25.27 pmol/mg) and declined to 6.90 pmol/mg by 48 hours. AQM was 
present at 0.25 hour but unlike AQ4 was absent at 48 hours. AQ4N was 
detected at 1 hour only. 
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Table 11. AQ4N and metabolites in H 29 tumour xenografts excised from 
nude mice. 
Time (hr) A04(pmol/mg ±SE) AOM(pmollmg ±SE) AQ4N(pmollmg ±SE) 
0 NO NO NO 
0.25 NO NO NO 
1.00 45.86+37.47 6.67+4.00 2.95 
24 NO NO ND 
48 2.27+0.36 NO NO 
. Data have been corrected for % recovery. NO=not detected. Values are 
pooled mean +SE for three mice. Where no SE is given values are means 
of two. 
Table 12. AQ4N and metabolites in KHT tumours excised from C3H mice 
Time (hr) AQ4(pmol/mg ±SE) AQM(pmol/mg ±SE) AQ4N(pmol/mg ±SE) 
0 NO NO NO 
0.25 4.80±3.61 2.73 NO 
1.00 11.85+6.63 NO NO 
24 NO ND ND 
48 ND ND ND 
Data have been corrected for % recovery. ND=not detected. Values are 
pooled mean +SE for three mice. 
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T~ble 13. AQ4N and metabolites in RIF- 1 tumours excised from C3H 
mice. 
Time (hr) A04(pmol/mg) AOM(pmollmg) AQ4N(pmol/mg) 
0 NO NO NO 
0.25 NO 0.58 NO 
1.00 NO NO NO 
24 3.17 NO NO 
48 2.88 NO NO 
Oata have been corrected for % recovery. NO=not detected. Values are 
mean results from two mice. 
Table 14. AQ4N and metabolites in SCCVII tumours excised from C3H 
mice. 
Time (hr) A04(pmol/mg ±SE) AQM(pmol/mg ±SE) AQ4N(pmol/mg ±SE) 
0 NO NO NO 
0.25 25.27 11.02 ND 
1.00 22.57+6.00 2.48+1.71 40.35+16.22 
24 1.83+0.97 15.47+15.47 NO 
48 6.90±2.76 ND NO 
Oata have been corrected for % recovery. NO=not detected. Values are 
pooled mean +SE for three mice. Where no SE is given values are means 
of two data points. 
5.3.3 Plasma 
AQ4N peaked at 1 hour after dosing, with the exception of plasma from the 
HT29 and NT (non tumour) group which peaked 15 minutes after dosing 
(Table 15). AQ4N was not detected in any animal, in any group, 1 hour after 
ip injection. AQM was variable from 15 minutes to 1 hour after dosing and 
only small amounts of this metabolite were detected in the plasma from 
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SCCVII and the HT29 groups after 1 hour post ip injection. Interestingly, 
and unlike the tumours, AQ4 was a minor metabolite in the plasma of C3H 
mice and the ratio of AQ4/ AQ4N ranged from 0.15- 0.005. 
Ta~le 1~. AQ4.N and meta~olit~s from the plasma of mice (all groups) at 
various time POints after dosing (Ip) with 250 mg/kg AQ4N 
Animal Metabolite Time (hr) 
Group 0.25 1.00 24 48 
NT AQ4 NO 2.96 NI NO 
AQM 34.66 31.00±14.34 NI NO 
AQ4N 717.05 554±231.48 NI NO 
RIF-1 AQ4 18.20±9.80 NO NO NO 
AQM 25.55±21.40 33.93±9.71 NO NO 
AQ4N 153.51±98.55 680.68±41.30 NO NO 
SCCV11 AQ4 14.69 6.18 17 .09±11 .59 NO 
AQM 48.92 37.86 1.812 NO 
AQ4N 147.53 378.36 NO NO 
HT29 AQ4 14.82±7.42 6.25 NO 1.26 
AQM 30.72±11.14 23.30 NO 1.31 
AQ4N 152.30±51.11 40.83±21.85 NO NO 
KHT AQ4 15.08 8.77 NO NO 
AQM 22.31 92.66±75.96 NO NO 
AQ4N 240.20 434.60±28.90 NO NO 
Data have been corrected for % recovery. Data are pooled values .for three 
mice and are expressed as pmol metabolite/ mg of tissue protem + SE. 
ND=not detected, NI=no information (due to sample damage or abs~nce). 
Where no SE is given, the values are the mean result from two mice. . 
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5.3.4 Livers 
Both AQ4 and AQM were detected in the livers of all animals (Table 16). 
Broadly speaking, the amount of AQ4 and AQM declined with time in the 
livers of the NT and RIF-1 animals. However, this trend was not observed in 
the livers of mice from the other groups. Interestingly, the amount of hepatic 
AQ4 only once exceeded the amount of the same metabolite detected in 
tumours (48 hour value in liver of HT29 mice versus 0.25 hour value in 
HT29 tumour). AQ4N was detected at 0.25 hour in the NT group but absent 
in all other animals apart from the KHT livers at 24 and 48 hours. 
5.3.5 Gall bladders 
AQ4N peaked after 15 minutes in KHT and RIF-1 animals and at 1 hour in 
the gall bladders from NT and HT29 groups (Table 17). From 15 minutes to 
1 hour post ip injection all animals, in all groups, showed a qualitatively 
similar profile of drug and metabolite concentrations in the order 
AQ4N>AQM>AQ4 (low AQ4/AQ4N ratio). However, this trend was not 
observed in the data from 1 hour to 48 hour. 
5.3.6 Muscle 
AQ4 declined in a general fashion from 0.25 hour to 48 hours in all animal 
groups. With the exception of the KHT mice, AQM levels appeared to 
increase from 15 minutes to 1 hour (Table 18). From 24 hour onwards, AQM 
was undetectable or very low in all groups investigated. From 15 minutes to 
1 hour metabolite concentrations were consistently detected in the order 
AQ4N>AQM>AQ4 (lOW AQ4/AQ4N ratios). AQ4N peaked after 15 minutes 
in the NT, SCCVII and KHT groups and at 1 hour in the RIF- 1 and HT29 
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groups. AQ4N was undetectable in all animals, in all groups, from 24 hours 
onwards. 
Ta~le 1~. AQ~N and metabolites from the livers of mice (all groups) at 
various time POints after dosing (ip) with 250 mg/kg AQ4N 
Animal Metabolite Time (hr) 
Group 0.25 1.00 24 48 
NT AQ4 39.00 9.13±2.71 12.14 9.58 
AQM 74.36 3.28±1.71 NO NO 
AQ4N 17.67 NO NO NO 
RIF-1 AQ4 41.27±34.02 11.73 22.00±13.10 9.78±4.72 
AQM 59.63±35.94 3.68 18.42 NO 
AQ4N NO NO NO NO 
SCCV11 AQ4 10.78 8.24 16.79±2.46 25.63±8.20 
AQM 5.53 NO 22.10±11.34 7.90 
AQ4N NO NO NO NO 
HT29 AQ4 28.714±16.66 7.40±0.38 7.81±1.66 110.13±83.47 
AQM NO 1.62±1.62 18.71±5.05 46.54 
AQ4N NO NO NO NO 
KHT AQ4 7.96±3.43 1.34 19.89±5.40 10.47±4.51 
AQM 9.58±2.28 7.16 5.46±1.46 29.35±9.20 
AQ4N NO NO 1.44 124.40 
Data have been corrected for % recovery. Data are pooled values for three 
mice and are expressed as pmol metabolite/ mg of tissue protein ± SE. 
ND=not detected. Where no SE is given, the values are the mean result of 
two mice. 
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Table 17. AC?4N ~nd m~tabolites from gall bladder tissue of mice (all 
groups) at various time POints after dosing (ip) with 250 mg/kg AQ4N 
Animal Metabolite Time (hr) 
Group 0.25 1.00 24 48 
NT AQ4 9.03 120.15 NI NO 
AQM 90.48 261.37±42.37 NI NO 
AQ4N 555.89 1368.95 NI NO 
RIF-1 AQ4 50.75 2.89 6.76 NO 
AQM 73.30 86.51 1.93 NO 
AQ4N 1415.54 358.85 6.83 NO 
SCCV11 AQ4 36.63 NI 81.49 3.41±2.38 
AQM 284.27 NI 135.00 NO 
AQ4N 380.89 NI NI NO 
HT29 AQ4 66.13 24.69±24.69 18.07 110.49±44.06 
AQM 76.52 1 03.46±1 03.4 NO 4.51 
AQ4N 239.05 920.64±577.0 NO NO 
KHT AQ4 22.28±11.30 59.92 623.25±98.90 9.28±1.45 
AQM 152.11 ±53.56 107.71 NO 5.16±5.16 
AQ4N 1321.45 497.59 NO NO 
Data have been corrected for % recovery. Data are pooled values for three 
mice and are expressed as pmol metabolite/ mg of tissue protein ± SE. 
ND=not detected, NI=no information (due to sample damage or absence). 
Where no SE is given, the values are the mean result from two mice. 
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Group 
Table 18. A~4N ~nd m~tabolites from the hind leg muscle of mice all 
groups) at vanous time POints after dosing (ip) with 250 mg/kg AQ4N ( 
~nimal Metabolite Time (hr) 
3roup 0.25 1.00 24 48 
NT AQ4 NO 4.74 NI NO 
AQM 10.91 19.09 NI NO 
AQ4N 88.22 56.17 NI NO 
RIF-1 AQ4 4.56 1.32 NO NO 
AQM 9.41 17.12 NO NO 
AQ4N 53.56 79.52 NO NO 
SCCV11 AQ4 1.84±1.24 0.50 NO NO 
AQM 13.89±5.46 89.36 NO NO 
AQ4N 29.86±23.18 24.26 NO NO 
HT29 AQ4 1.60±0.87 4.59±3.39 NO 1.29 
AQM 23.07±19.41 62.60±38.40 NO 1.31 
AQ4N 113.22±78.06 180.79±80.88 NO NO 
KHT AQ4 6.06±2.41 NO NO 4.32 
AQM 29.50±2.32 6.99±1.07 NO NO 
AQ4N 159.77±11.30 53.51±21.16 NO NO 
Data have been corrected for % recovery. Data are pooled values for three 
mice and are expressed as pmol metabolite/ mg of tissue protein ± SE. 
ND=not detected, NI=no information (due to sample damage or absence). 
Where no SE is given, the values are the mean of two mice. 
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5.4 Conclusions 
1) Both metabolites of AQ4N (AQM and AQ4) were detected in each tumour 
type assayed and, in general, AQ4 was found to be the predominant 
metabolite detected. SCCVII tumours showed the most extensive 
metabolite profile and along with RIF-1 and HT 29 were found to have AQ4 
present at 48 hours. However, no clear correlation was found between 
levels of AQ4 in tumours and the in vivo sensitivities of these neoplasms to 
AQ4N based treatment as published by Cole et a/ (1995). 
2) Hepatic tissue from all mice was found to contain both AQ4 and AQM . 
. There was a high degree of within mouse and within group variability. 
However, the amount of AQ4 in liver rarely exceeded the amount found in 
tumour material. 
3) Plasma was found to contain AQ4N, AQM and AQ4. Unlike tumours, AQ4 
was shown to be the minor metabolite detected. 
4) Metabolite profiles were found to be highly variable in both gall bladder 
tissue and muscle. However, the high levels of AQ4N found in gall bladder 
indicate that liver excretion was a major route of elimination. 
In summary, AQ4 and AQM were detected in the rodent and human tumours 
xenografts of C3H mice, which demonstrated that in the in vivo setting the 
active metabolite of AQ4N (AQ4) was able to reach its cellular target. 
Metabolites were also found in hepatic and extra hepatic tissues. 
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Chapter 6 
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Chapter six 
6.1 General Discussion 
The HPLC method used throughout the course of this work was a 
modification of the method originally described by Dr M. Graham (personal 
communication). The reduction of flow rate from 2 mUmin to 1 mUmin and 
the acetonitrile concentration from 320/0 to 30% facilitated an accurate and 
reproducible assay for the quantitation of AQ4N and the two and four 
electron reduced metabolites AQM and AQ4, respectively. The quantitation 
of the two electron reduced mono-N-oxide, AQM, proved critical to our 
understanding of AQ4N metabolism as the generation of this metabolite 
appeared to be the initial event in the metabolism of AQ4N. An exception to 
this observation was apparent in the experiment using the CPR! HO system 
where AQ4 is produced without any detectable AQM. A possible 
explanation for this finding is discussed later. 
The reductive metabolism of AQ4N and AQM has been shown to be an 
enzymatic process occurring in microsomes and dependent on hypoxic 
conditions and the presence of reduced cofactor. There is a marked 
preference for NADPH over NADH as reduced cofactor, a finding which 
supports the involvement of cytochrome P450 reductase (CPR) as opposed 
to NADH cytochrome b5 in the bioactivation of both AQ4N and AQM. It must 
be stressed, however, that CPR alone does not seem to be able to 
metabolise either compound. This is based on the following observations. 
(1) Semi purified rat hepatic CPR required exogenous haem to support 
AQ4N metabolism in the presence of NADPH. (2) The general CYP 
inhibitors ketoconazole (KET) and carbon monoxide (CO) inhibited 
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completely the metabolism of both A04N and AOM. (3) Microsomes from 
human Iymphoblastoid cells containing a gene insert for CPR were unable 
to metabolise A04N. The apparent inability of CPR per se to mediate the 
metabolism of A04N may have important clinical implications which may 
favour the use of this particular prodrug over other bioreductives such as 
tirapazamine. Indeed, the inability of CPR alone to metabolise A04N may 
explain the lack of systemic toxicity observed in rodents given AQ4N 
compared to similar doses of tirapazamine (Friery 1997 and McKeown et at 
1996). The molecular basis underlying tirapazamine toxicity may be due to 
CPR mediated one electron reduction of the drug to a reactive nitroxyl 
radical followed by redox cycling with the subsequent generation of a 
systemically damaging reactive oxygen species. Indeed mitoxantrone, a 
structural analogue of A04N, does not appear to undergo detectable redox 
cycling in MCF-7 cells (Fisher and Patterson 1992). A04 has been shown 
to undergo oxidative metabolism and, in rat and human liver microsomes, 
the compound is converted to AOM and represents the reverse process of 
the anaerobic dependent two electron reduction of AQM to AQ4. Oxidative 
metabolism of A04 shows an absolute requirement for NADPH and air. The 
amount of AQM detected was small compared to the reverse process (two 
electron reduction of AOM to AQ4) and involvement of CYP is likely based 
on the fact that oxidative metabolism in rat and human was inhibited in 
incubates containing the CYP inhibitors ketoconazole and carbon 
monoxide. 
The absence of detectable metabolism of either A04N or AOM in human or 
rat microsomal incubates purged with CO or preincubated with KET, has 
already been mentioned, and infers a major involvement of the cytochrome 
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P450 haemoproteins (CYP) in the anaerobic dependent activation of both 
N-oxides. CYP has been shown to metabolise several other N-oxides 
under anaerobic conditions in rodents including tiaramide, imipramine, N,N-
dimethylamine and tirapazamine N-oxides (Sugiura et a/1976, Powis and 
Wincentsen 1980, Walton and Workman 1990 and Riley et a/1993). In 
particular, the statistically significant increase (p<0.01) in metabolism of 
AQ4N to both metabolites and AQM to AQ4 in microsomes from isoniazid 
(ISO) pretreated animals compared to untreated control microsomes infers a 
role for the ethanol inducible CYP 2E subfamily. Furthermore, the 
involvement of CYP 2E in the metabolism of AQM to AQ4 was confirmed by 
preincubation, of the mechanism based CYP 2E inhibitor 
diethyldithiocarbamate (DIE), with ISO pretreated microsomes. Specifically, 
DIE preincubation abolished the generation of AQ4 from AQM, in 
experiments using AQ4N as substrate, and reduced the formation of AQ4 
from AQM by around 700/0 in incubates using AQM as substrate. However, a 
somewhat perplexing finding was that the same CYP 2E inhibitor only 
reduced the formation of AQM from AQ4N to 430/0 compared to ISO treated 
microsomes preincubated with AQ4N in the absence of DIE. These results 
may suggest that, in addition to CYP 2E induction, ISO treatment may lead 
to the up regulation of another enzyme that is capable of anaerobically 
reducing AQ4N to AQM (via a two electron reduction) but which is 
uninhibited by DIE. 
AQ4 production was significantly enhanced in experiments using either 
AQ4N or AQM incubated with microsomes from phenobarbitone (PB) 
pretreated animals. This observation is consistent with the involvement of 
CYP 28. However, CYP 28 seems to catalyse only the two electron 
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reduction of AQM to AQ4 as AQM production in PB induced microsomes pre 
incubated with AQ4N was not greater than the generation of the same 
metabolite in untreated control microsomes. The role of CYP 2B in the 
metabolism of AQM to AQ4 in BP induced microsomes (whether the initial 
substrate was AQ4N or AQM ) was substantiated by the use of the CYP 2B 
inhibitor metyrapone (MET). Inhibition of AQ4 from AQM was approximately 
80% in incubates preincubated with 10 JlM MET compared to controls. In 
experiments using AQ4N as substrate for PB induced microsomes, the 
same concentration of MET inhibited completely the formation of AQ4 and 
decreased the formation of AQM by 2.5 fold. The latter observation was 
surprising since PB induction did not enhance the production of AQM 
compared to untreated microsomes. A possible explanation for this is the 
involvement of an unidentified enzyme which is inhibited by MET but not 
increased by PB pretreatment. 
Microsomes from male Sprague-Dawley rats pretreated with pregnenolone 
16-carbonitrile (PCN) produced a similar quantity of AQM from AQ4N but the 
production of AQ4 was significantly reduced compared to tween 80 (TWE) 
controls. In a similar fashion, the metabolism of AQM to AQ4 was reduced in 
microsomes from PCN induced animals. These results indicate that the rat 
CYP 3A protein does not contribute to the two electron reduction of AQM to 
AQ4. Furthermore, this lack of CYP 3A mediated reduction of AQM occurs in 
experiments where AQ4N is converted to AQ4 via AQM or when AQ4 is 
produced directly from substrate AQM. Repression of AQ4N conversion to 
both metabolites and AQM to AQ4 was observed also in microsomes from 3-
methylcholanthrene (3 MC) pretreated animals, implying a lack of 
involvement of CYP 1A in the total metabolism of either AQ4N or AQM. The 
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molecular basis for the repression of AQ4N or AQM metabolism in 
microsomes from PCN or 3 MC induced animals may involve the availability 
of cellular haem for newly translated CYP apoprotein. Indeed haem has 
been identified as a post transcriptional regulating factor in the expression 
of CYP (Bhat and Padmanaban 1988 and Padmanaban et a/1989). In this 
scenario UT, ISO or PB induced microsomes contain sufficient CYPs 2B and 
2E to metabolise either compound. Furthermore, these apoproteins have 
access to a predetermined amount of haem to synthesise functional 
haemoproteins. In PCN and 3MC induced microsomes an abundance of 
CYP 1 A and 3A exist respectively and these apoproteins may restrict the 
availability of haem to the isoforms of CYP known to metabolise both AQ4N 
and AQM, namely CYP 28 and 2E. Alternatively, the induction of CYP 1 A 
and 3A may interfere with the potential of the cell to produce CYPs 2B/2E by 
down regulatio~ of transcription, translation or a combination of both. 
Furthermore, the stability of mRNA or apoprotein for either CYP 2B/2E may 
become compromised. The net result of these cellular events is a reduction 
in the metabolism of AQ4NI AQM. 
In rat microsomes the kinetics of AQ4N metabolism conformed to a classical 
Michaelis-Menten type model. This was true for the conversion of AQ4N to 
the two electron reduced metabolite AQM (Km= 38.76 JlM, Vmax= 0.92 
nmol/mg/min), the four electron reduced cell cytotoxin AQ4 (Km= 5.65 JlM, 
V max= 0.13 nmol/mg/min) and for the kinetics of total substrate turnover (sum 
of metabolites) (Km= 30.29 JlM, Vmax= 1.05 nmol/mg min). However, when 
AQM was used as substrate the velocity of AQ4 formation versus AQM 
concentration provided data which were best described by sigmoid kinetics. 
These findings indicate a cooperative two electron reduction of AQM to AQ4 
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with a calculated Hill coefficient (n) of 3.0. The calculated value for n infers 
there are three binding sites for AQM within the enzyme molecule and 
catalysis is most effective when these molecules are bound to the enzyme. 
In such a system the binding of these activating molecules may change the 
three dimensional conformation of the enzyme to a state which favours 
catalysis. The current findings do not exclude the possibility that AQM 
molecules may alter the conformation of the CPR molecule and hence make 
the passage of electrons from CPR to CYP more effective. 
Apart from differences in kinetic behaviour, the Km values for the total 
. metabolism of AQ4N (to AQM and AQ4) or the two electron reduction of 
AQM to AQ4 are similar, 30.29 JiM and 27.00 JiM respectively. This is 
consistent with the findings of the induction/inhibition experiments and 
suggests the same enzyme system(s) are responsible for the metabolism of 
both compounds. However, the V max obtained from experiments using AQM 
as substrate, exceeds the corresponding value for the total substrate 
turnover of AQ4N. This leads to the conclution that AQM is a better 
substrate for rat liver microsomes, characterised by the higher CLint value. It 
is noteworthy that the kinetic analysis of both AQ4N and AQM produce Km 
values which are approximately seventeen fold lower than the published 
value for indicine N-oxide (Powis and Wincentsen 1980) and between 
approximately two and five fold lower than the corresponding values for 
imipramine, tiaramide and N, N-dimethylaniline N-oxide respectively 
(Sugiura et a/1977). Although all six compounds had broadly similar Vmax 
values, AQ4N and AQM would appear to be better substrates for CYP 
reduction as reflected in their higher CLint values. 
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In human liver microsomes it has been shown unequivocally that the 
anaerobic dependent metabolism of AQ4N is a process mediated by the 
GYP 3A subfamily of enzymes. This is based on the following experimental 
findings. Firstly, the metabolism of AQ4N to the two (AQM) and four (AQ4) 
electron reduced compounds, as well as total substrate turnover (sum of 
AQM plus AQ4), correlated significantly (p<0.01) with benzoxyl resorufin 0-
dealkylase (BROD) and tamoxifen N-demethylase (TND) activities, both of 
which are recognised probes for GYP 3A. In experiments using AQM as 
substrate a similar finding emerged, namely the two electron reduction to 
AQ4 correlated significantly with BROD activity and with TND activity. 
Metabolism of both AQ4N or AQM did not however correlate with marker 
activity for the other human hepatic phase 1 enzymes namely CYP 1A, 2C 
or 20. However, when AQM was used as substrate, a significant correlation 
(p<0.05) between the two electron reduction to AQ4 and coumarin 7-
hydroxylase activity (GYP 2A marker) was found. Secondly, the metabolism 
of AQ4N in microsomes preincubated with 50 JlM TAO, a known CYP 3A 
inhibitor, abolished the production of AQ4 and inhibited the formation of 
AQM by about 84% (mean of three determinations in three livers). 
Furthermore, ANF had no significant effect on the metabolism of AQ4N, 
indicating that GYPs 1 A, 2C and 2A were not involved in the metabolism of 
AQ4N to either the two or four electron reduced metabolites. The results of 
these inhibitor experiments were entirely consistent with the correlation 
data. Finally, human Iymphoblastoid cell microsomes from cells transfected 
with a functional GYP 3A4 gene were able to support the anaerobic 
metabolism of AQ4N to both metabolites. The metabolism was inhibited 
totally in the presence of 50 JlM TAO. By way of comparison, AQ4N 
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metabolism was not detected in incubates containing human microsomes 
from cells transfected with an insert for CYP 286 or CPR. 
The kinetics of AQ4N metabolism in three separate human livers conformed 
to a classic Michaelis-Menten model. Furthermore, the calculated Km 
values for the two electron reduction of AQ4N to AQM, followed by the 
subsequent two electron reduction of AQM to AQ4 and the total metabolism 
of AQ4N (sum of AQM and AQ4) were similar, suggesting that the same 
enzyme was responsible for the metabolism of the prodrug in all three 
individuals. The V max values obtained reflected the extent of AQ4N 
metabolism within the three individuals, such that HLM 55 could be 
described as a good metaboliser of AQ4N having the highest V max and CLint 
value while HLM 50, a poorer metaboliser, had a lower Vmax and CLint value 
accordingly. Furthermore, the Km value for total AQ4N metabolism in 
untreatead rat microsomes was similar to the corresponding values 
obtained in the three human livers. However, due to the higher Vmax 
obtained in rat, the CLint value for the rat mediated metabolism was found to 
be between 6.5 and 3.4 fold higher. From these data it was apparent that 
AQ4N is a better substrate for rat than human liver microsomes. 
The results demonstrate, for the first time, that AQ4N can be anaerobically 
metabolised in human renal and colonic tumours. Furthermore, the 
metabolism of the prodrug within both renal and colonic neoplasms is 
consistent with the involvement of CYP, as metabolite production was 
inhibited completely in the presence of the CYP inhibitor CO. 
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The anaerobic metabolism of AQ4N by human CYP 3A enzymes provides a 
rational drug target for AQ4N based treatment regimes. To date, CYP 3A 
enzymes have been detected in a broad spectrum of human cancers 
including colon (McKay et a/1993), colorectal (de Waziers et a/1991), soft 
tissue sarcomas (Murray et a/1993), breast (McKay et a/1993 and Chabot 
et a/1997), lung (Kivitso et a/1995), oesophagus (Murray et a/1994), liver 
(Fritz et a/1993), bladder (Murray et a/1995), prostate (Murray et a/1995) 
and stomach (Murray et a/ 1998). Importantly, some of these neoplasms 
appear to express CYP 3A whereas its presence in the corresponding 
normal tissue is undetectable (Murray et a/1994, Murray et a/1995, Murray 
et a/1998 and McKay et a/ 1993). This latter observation presents the 
possibility of AQ4N undergoing entirely tumour specific bioactivation. 
Although the mechanism underlying the reductive activation of AQ4N has 
not been studied, a number of N-oxides including tiaramide N-oxide and N, 
N-dimethylaniline have been shown to undergo type II spectral interactions 
with CYP in the absence of oxygen (reviewed by Lindeke and Paulsen-
Sorman 1988). These observations have led Patterson (1993) to speculate 
on a general mechanism for anaerobic dependent reduction of N-oxides by 
haemoproteins, including CYPs. This mechanism could apply to the 
anaerobic dependent metabolism of AQ4N and AQM. Initially CYP is one 
electron reduced by CPR, a process that is a prerequisite for N-oxide 
binding to the haem centre. Secondly, the CYP enzyme and the N-oxide 
form a enzymel substrate complex, with the N-oxide moiety binding to the 
Fe2+ ion of the porphyrin ring and the rest of the substrate binding to the 
active site within the CYP molecule. Thirdly, a second one electron 
reduction by CPR produces the apoprotein/FelV=O species and an amine. 
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Finally, the amine is released and a molecule of water is formed. The 
sequence is shown in Figure 60. 
In addition to N-oxide/haem interactions, the ability of a drug to fit snugly into 
the active site of an enzyme is critical for catalysis. With this in mind, the 
metabolism of AQ4N and AQM by CYP 3A enzymes is further supported as 
the most important interaction between an amino acid within the active site 
of CYP 3A and a newly docked substrate is thought to be the hydrogen 
bond donor asparagine 74 (Asn 74) and a hydrogen bond acceptor on the 
substrate molecule (reviewed by Smith et al 1997a). Furthermore, the 
distance between this interaction and the site of metabolism has been 
proposed to be 6.81 + 1.27 Angstroms (reviewed by Smith et a/1997a). The 
distance between the 5 or 8 hydroxy group on AQ4N or AQM and the 
oxygen atom of the N-oxide group is 9 Angstroms (Teesdale- Spittle, 
personal communication). However, it is possible that free rotation of the N-
oxide group around sigma bonds within the alkylamino side arms means 
the proposed distance of 6.81 Angstroms between hydrogen bonding and 
site of metabolism is entirely feasable. Rotation of the N-oxide group 
around a sigma bond can occur without imposing any energetic constraints 
on the AQ4N molecule (P Teesdale- Spittle, personal communication). 
Secondly The large active site of CYP 3A4 is very accessable to N-alkyl 
based groups and has been proposed to change conformation. in order to 
account for its broad range of substrate activities (reviewed by Smith et al 
1997b). 
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Fig 60. Proposed mechanism of NADPH dependent cytochrome P450 
mediated reduction of N- oxides (adapted from Patterson 1993). See text 
for details. Steps are: 1) one electron reduction of CYP. 2) Enzyme 
substrate complex formation. 3) second one electron reduction and 4) 
amine relaease 
In addition to CYP 3A mediated metabolism of AQ4N, semi purified rat CPR, 
in combination with haem, was shown to metabolise AQ4N to AQ4, a 
process dependent on both NADPH and anaerobic conditions. The 
absence of detectable AQM in this experiment was, at first, hard to 
rationalise. However, CPR is known to have at least three binding sites for 
haem (Yoshinaga et al 1982) and, in the presence of molecular oxygen, 
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degrades haem to biliverdin (Docherty et a/1982 and Masters and Schacter 
1976). Under conditions of hypoxia it is possible that the CPR! haem 
complex acts as a makeshift haemoprotein unable to oxidise haem but 
instead shuttling electrons through ,the bound haem moieties on to the N-
oxide groups of AQ4N with the subsequent oxidation of NADPH. In this 
scenario both N-oxide groups are simultaneously reduced to tertiary 
amines, by a similar mechanism to that outlined in Figure 60, and so AQ4 is 
produced but not AQM. Addition of haem oxygenase (HO) to this system did 
not enhance AQ4N metabolism but produced a slight, albeit significant 
(p<0.05), repression of metabolism. The reason for this observation is at 
present unknown. AQ4N was also a substrate for purified nitric oxide 
synthase (NOS). The appearance of both AQM and AQ4 under hypoxic 
conditions may not be entirely surprising as NOS is known to be a CYP type 
haemoprotein (White and Marietta 1992). Indeed the amino acid sequence 
of NOS enzymes contain a high degree of homology with CPR (Bredt et al 
1991) and may allow the enzyme to function as a chimeric CPR-CYP 
enzyme (reviewed by Schmidt et a/1993). 
So far "discussion has focused on the metabolic conversion of AQ4N to its 
metabolites in subcellular fractions, human tumours ex vivo and by semi 
purified and purified enzyme systems. The in vivo metabolism of AQ4N in 
tumour and non tumour bearing C3H mice was conducted with a view to 
qualitatively determine whether the metabolites of AQ4N could be identified 
in the rodent tumours and so confirm metabolism of AQ4N in an in vivo 
model as opposed to an in vitro one. Firstly, cytotoxiC AQ4 was detected in 
all rodent neoplasms. The amount of AQ4 detected exceeded the amount of 
AQM and AQ4N (high AQ4/ AQ4N ratio) in all tumours at all times (with the 
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exception of one result in SCCVII tumours at 1 hour). Using the same C3H 
murine model, an early study by Cole et al (1995) found that AQ4N was 
particularly effective in retarding the growth of the RIF- 1 and SCCV11 
tumours but had little effect on KHT tumours. Although the present study 
failed to identify a definite trend between the amount of AQ4 detected in 
these tumours and the in vivo sensitivity of the tumours to AQ4N 
administration (from the study of Cole and co workers) it is noteworthy that 
AQ4 is detectable at 48 hours in both the SCCVII and RI F- 1 neoplasms but 
absent in the KHT tumours from 1 hour onwards. The detection of AQ4N 
metabolites within the livers of C3H mice is likely to reflect the activity of 
. murine CYPs mediating the reductive metabolism of the anthraquinone in 
areas of low oxygen tension. Indeed the pericentral region of the liver is 
known to be hypoxic to some extent (reviewed by Woodrooffe et a/1995). In 
general, the lower AQ4/ AQ4N ratios found in plasma, muscle and gall 
bladder tissue, compared to tumour and liver, were probably due to the 
absence of appropriate reductase enzymes, presence of too much oxygen 
or a combination of both of these factors. 
6.2. Future work 
The metabolism of AQ4N, and AQM, have been described in detail and the 
enzymes responsible for the bioreduction of both of these compounds 
identified. A number of interesting questions have arisen as a result of this 
work and could be the focus of future research, these are outlined below. 
1) The specific isoforms of CYP responsible for AQ4N metabolism in the 
human renal and colonic tumours could be identified by the use of isozyme 
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specific inhibitors pre incubated with AQ4N and NADPH under hypoxic 
conditions. Indeed this work could be extended to look at the metabolism of 
AQ4N in tumours other than those of renal of colonic origin. 
2) Although the GYP 3A subfamily as a whole, and in particular the CYP 
3A4 isoform, have been shown to bioactivate AQ4N, the individual 
contribution of GYP 3A5, 3A3 and CYP 3A7 remains to be firmly 
established. With this in mind, a series of metabolism experiments using 
cells transfected with cDNA for each isoform would determine which of 
these GYPs could contribute to the metabolism AQ4N and AQM. 
3) The expression of GYP 3A enzymes in many tumours has been 
investigated by a number of workers. However, correlations between CYP 
3A activity and the type, origin, clinical grade, invasiveness, metastatic 
potential and degree of differentiation of human tumours have not been 
evaluated. This kind of detailed information would establish which 
particular tumours are most suitable for AQ4N (or possibly AQM) treatment. 
4) The preliminary work with purified rat brain NOS and the CPR! HO system 
has shown that these enzymes are capable of AQ4N metabolism. However, 
further work is required to establish whether these systems have any 
relevance in vivo. 
5) Although the results of the preliminary in vivo metabolism experiments 
show some qualitative trends, an in depth pharmacokinetic analysis of 
AQ4N in rodents, covering a longer time course and using more animals per 
time point may clarify and enhance the present findings. 
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6) A detailed investigation into the kinetics of AQM metabolism in human 
tissue may, like in the rat, show that this compound is a better substrate for 
human microsomal enzymes than AQ4N. Furthermore, the aerobic toxicity 
of AQM to cell lines in vitro and in rodents in vivo should be evaluated as 
this compound may prove to be a superior prodrug to AQ4N. 
6.2 1 Concluding remarks 
AQ4N bioreduction has been shown to occur in a variety of rodent and 
human tissue fractions in vitro, in rodent tumours in vivo and in ex vivo 
samples of human tumours. Furthermore, GYP and other haem based 
enzymes specifically contribute to the metabolism of this prodrug. In rats, 
GYPs 2B and 2E contribute to the reductive activation of AQ4N while in 
humans, AQ4N is bioreduced by GYP 3A enzymes. These enzymes have 
been detected in a broad spectrum of human cancers. 
Collectively, these findings suggest that AQ4N based prodrug therapy 
should be considered as an ideal treatment regime for patients bearing 
solid tumour burdens. Such tumours are known to contain significant 
numbers of hypoxic cells and express GYP 3A enzymes which, in certain 
. cases, are found in higher amounts than in normal tissue. 
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